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ABSTRACT 
Articular (hyaline) cartilage protects the subchondral bone from the high mechanical load 
during joint movement. This mechanical function of articular cartilage largely relies on the 
specialized composition and organization of the extracellular matrix deposited by chondrocytes, 
specifically, aggrecan, type II collagen, and sulfated glycosaminoglycans. The avascular nature of 
articular cartilage prevents access to progenitor cells and factors that mediate the endogenous 
healing response inherent in many other tissues. Thus, focal defects that result from traumatic 
injuries in articular cartilage do not heal and the intense biomechanical loading environment of the 
tissue leads to the painful and debilitating joint disease osteoarthritis.  
Efforts to develop mesenchymal stem cell (MSC)-based functional cartilage regeneration 
are hindered by the unstable phenotype that chondrocytes derived from these cells adopt using 
common cartilage tissue engineering strategies. Typically, MSC-derived chondrocytes (MdChs) 
express a transient articular phenotype before further differentiating through the stages of 
endochondral ossification, leading to the hypertrophic phenotype. Hypertrophic chondrocytes, 
driven by the transcription factor RUNX2 (Runt-related transcription factor 2), stop producing and 
start degrading the structural matrix macromolecules aggrecan and type II collagen, compromising 
the mechanical integrity of the overall tissue. Therefore, biological interventions that suppress 
chondrocyte maturation and encourage matrix retention can improve the functional outcome of 
MSC-derived cartilage tissues.  
This thesis focuses on developing a self-regulatory RUNX2 silencing gene circuit to 
xx 
 
improve accrual of articular cartilage-specific matrix by MSC-derived chondrocytes via tunable 
negative-feedback regulation of RUNX2 activity. Specifically, we engineered a synthetic cis 
promoter to initiate RNA interference of Runx2 exclusively during chondrocyte hypertrophy. To 
induce chondrocyte-specific RUNX2 silencing, synthetic cis promoters were engineered with a 
single or multiple copies of cis-enhancers upstream of the Col10a1 basal promoter. We showed 
that these promoters can direct transcription exclusively in pre-hypertrophic and hypertrophic 
chondrocytes with minimum activity in undifferentiated progenitor cells. Integrating the cis 
promoter and RNAi of Runx2 into a gene circuit, we further demonstrated that the cis-RUNX2 
silencing circuit can: 1) induce loss of RUNX2 function specifically during chondrocyte 
hypertrophy, 2) resist elevation of intracellular RUNX2 activity via negative-feedback regulation, 
and 3) provide adjustable levels of RUNX2 suppression.   
With these gene circuits, we observed improved matrix accumulation and downregulation 
of hypertrophy markers during chondrogenesis of a murine chondrogenic cell line and primary 
MSCs. The successful engineering of this gene circuit highlights the potential to introduce artificial 
regulatory machinery into mammalian cells to modulate their behavior and optimize tissue 
engineering outcomes. 
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Chapter 1 Introduction 
1.1 Background and Motivation: Articular Cartilage and Its Injuries 
Articular (hyaline) cartilage covers the ends of long bones with a low-friction gliding 
surface1. It also protects the subchondral bone from the high mechanical load during joint 
movement by redistributing the impact2–5. This unique mechanical function of articular cartilage 
largely relies on the specialized composition and organization of the extracellular matrix (ECM) 
deposited by chondrocytes6, which reside within the dense network of their secretion (Figure 1-
1). Among the matrix molecules, type II collagen, aggrecan, and sulfated glycosaminoglycans 
(sGAGs) are the major contributors to the mechanical integrity. sGAGs are negatively-charged 
side chain molecules of aggrecan that attract water from the aqueous synovial environment into 
cartilage tissue. This generates a hydrostatic swelling pressure that resists the compressive loads 
exerted on cartilage7,8.  Type II collagen forms fibrils that provide the tensile strength needed in 
articular cartilage to resist the swelling pressure due to aggrecan and tensile loads that arise 
throughout the tissue during daily activities9. 
 
Figure 1-1. Schematic of articular cartilage matrix regions. 
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Traumatic joint injuries occur frequently, especially among young and active populations10. 
These traumas often result in either partial- or full-thickness cartilage defects that can penetrate 
down to the subchondral bone11,12. The lack of blood vessels in articular cartilage prevents the 
injury sites from accessing progenitor cells and nutrients, therefore hampering the potential of 
spontaneous repair of the defect13,14. When these defects are left untreated, the disrupted tissue 
integrity leads to abnormally high loads on the remaining healthy cartilage15,16. Under excessive 
mechanical stress, chondrocytes produce inflammatory cytokines, such as IL-1β (interleukin-1 
beta)17,18 and TNFα (Tumor necrosis factor-alpha) 19,20, which further induce the expression of 
matrix-degrading enzymes21–24 and suppress the synthesis of aggrecan or type II collagen25,26. Such 
long-term overload and injury/stress-induced inflammatory responses accelerate the deterioration 
of the remaining healthy cartilage, eventually leading to posttraumatic osteoarthritis (PTOA, 
Figure 1-2)27. Therefore, various clinical repair strategies have been developed with the goal of 
repairing the damaged cartilage and preventing further loss of cartilage. 
 
Figure 1-2. Injury/stress-induced inflammatory responses in articular cartilage. 
1.2 Current Clinical Repair Strategies for Articular Cartilage Traumatic Injuries  
Three surgical procedures are commonly used to clinically repair articular cartilage 
traumatic focal defects: microfracture, osteochondral transplantation28, and autologous 
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chondrocyte implantation. Each has advantages and disadvantages that drive the clinical decision-
making process, but none fully restore cartilage function. 
Microfracture is one of the most frequently performed techniques to stimulate the 
spontaneous repair of full-thickness cartilage defects29. As a relatively simple procedure, the repair 
process involves debridement of the defects, removal of calcified cartilage, and perforation of the 
subchondral bone plate underneath the injury sites to allow bone marrow and blood to be released 
into injury sites. The arrival of bone marrow mesenchymal stem cells (MSCs) initiates the repair 
process and eventually forms cartilaginous tissues. As an inexpensive and minimally invasive 
procedure with short recovery time and low morbidity30,31,32,33, microfracture is generally 
prescribed for repairing small defects (e.g., <2cm2) in younger patients34. However, in many cases, 
fibrocartilage forms within the repair site that is not as stiff as hyaline cartilage35–37; therefore, this 
tissue cannot adequately support the physiologic loading conditions in the knee and hip joints. The 
inferior mechanical properties of the fibrocartilage consequently affects the long-term 
effectiveness of the microfracture procedure, typically resulting in degeneration of the repair tissue 
and early onset of PTOA34,38.  
Osteochondral transplantation provides rapid restoration of joint mobility by replacing 
focal defects with hyaline cartilage39. Depending on the actual size of the defect, either autografts 
or allografts can be used. For autograft transplantation, single or multiple cartilage plugs, including 
the subchondral bone tissue, are harvested from the low weight-bearing area of the patient’s knee 
before being implanted into the injury sites. Although this method immediately restores most of 
the mechanical function at the defect sites, problems such as insufficient donor tissues, donor site 
morbidity, and damages to the harvested autografts often challenge its clinical outcome40. To 
eliminate these problems, allografts are also used in this type of repair, especially for larger lesions 
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(e.g., >3cm2)39. Allografts are associated with other risks, such as disease transmission and 
immune responses by the host system. In addition, donor grafts from the tissue banks are not 
freshly harvested and the processing procedures often induce some cell death as well as reduces 
the mechanical strength of the tissues41,42. 
Autologous chondrocyte implantation (ACI) is also performed to repair large cartilage 
lesions (e.g., 2-12cm2)43,44. ACI is a two-step surgical procedure that starts with harvesting a piece 
of healthy tissue from the low weight-bearing region of the patient’s cartilage. Following the first 
surgery, chondrocytes within the removed cartilage are isolated and expanded in vitro before being 
injected back into the chondral defects beneath a periosteal patch in a second surgery45. More 
recently, matrix-induced autologous chondrocyte implantation (MACI) has been adopted to 
avoid complications associated with the use of periosteum such as hypertrophy and 
calcification46,47. Instead of relying on the sutured periosteal cover to contain the implanted 
chondrocytes, cells were seeded on a bilayer membrane made of type I/III collagen before being  
implanted into the defects using fibrin glue48. Both ACI and MACI require monolayer expansion 
of articular chondrocytes to increase the yield of cells so that only a small piece of cartilage is 
needed to repair a larger defect. However, studies have shown that primary articular chondrocytes 
have limited potential to proliferate and tend to dedifferentiate during in vitro expansion49. Among 
young patients, ACI has demonstrated 60% to 90% good-excellent clinical results after 1 to 11 
years; however, aging has shown to decrease not only quantity but also the growing potential of 
human chondrocytes, further limiting the effectiveness of ACI in certain patient populations50–52.  
1.3 Cartilage Tissue Engineering: from Chondrocytes to MSCs  
To overcome the limitations of the current clinical repair options, tissue engineering 
solutions have been proposed to generate neotissues containing sufficient structural molecules 
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(aggrecan and type II collagen) to restore mechanical function of the damaged articular cartilage. 
Cells, scaffolds, and culture conditions are three essential components of tissue engineering, and 
synergistic interaction among them contribute to the functional success of an engineered cartilage 
tissue. Primary chondrocytes remain the only type of cells that have been approved by the FDA to 
repair articular cartilage. Since 1994, articular chondrocyte-based repair strategies have evolved 
from the scaffold-free implantation in ACI, to collagen membrane-immobilized delivery (MACI, 
Vericel corporation, MA), and eventually to the chondrocyte-encapsulated 3D scaffolds (e.g., 
NeoCart by Histogenics corporation, MA, currently in clinical trial). While the development of 
biomaterial scaffolds and chondro-conductive culture environments has progressed significantly 
over the past two decades, the problems associated with the availability and expansion of articular 
chondrocytes still limits the success of tissue-engineered cartilage products. Therefore, different 
types of cells such as mesenchymal stem cells (MSCs)53,54, embryonic stem cells55,56, induced 
pluripotent stem cells (iPSCs)57,58, and even dermal fibroblasts59 have been examined as an 
alternative to articular chondrocytes for cartilage regeneration. 
MSCs have emerged as a promising candidate as these pluripotent stem cells can 
differentiate into chondrocytes60,61and have a high proliferative potential during in vitro 
expansion61,62,63. Initially observed at sites of tissue injury by pathologist J. Cohnheim in 186764, 
they were first isolated from the bone marrow of guinea-pigs by A. Friedenstein in 197065. MSCs 
are typically defined by 1) high clonogenicity; 2) lack of epitopes for hematopoietic cells and 
presence of keys epitopes associated with non-hematopoietic cells; and 3) ability to differentiate 
into adipocytes, chondrocytes, and osteoblasts using defined supplements in vitro (trilineage 
differentiation)66. Many factors have been investigated to encourage the formation of articular 
cartilage from MSCs, including growth factors, scaffold designs, oxygen tension and mechanical 
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cues. A classic chondrogenic induction cocktail contains high-glucose basal medium, 
dexamethasone, ascorbic acid, and most importantly growth factors such as TGF-βs (transforming 
growth factors)67–69, BMPs (bone morphogenetic proteins)70,71, and IGFs (insulin-like growth 
factors)69,72. Besides these factors that promote the production of aggrecan and type II collagen 
during differentiation, FGFs (fibroblast growth factors) have also been shown to improve 
chondrogenesis of MSCs when they are supplemented during the expansion of these cells73–75. In 
addition to the use of growth factors, different types of scaffolds have been developed to support 
MSC-based cartilage repair. Natural materials (e.g., agarose76, alginate77, chitosan78, collagen79, 
and hyaluronic acid80) and synthetic polymers (e.g. PCL81, PEG82, PGA83, and PLGA84) have all 
been used individually or combined to support chondrogenesis of MSCs. Moreover, the positive 
roles of mechanical stimuli, such as shear and dynamic compression, in maintaining of the well-
being of chondrocytes have received substantial attention85,86. Because of these findings, 
bioreactors that exert a physiologic level of shear or direct compressive loading to cells have also 
been developed to improve cartilage tissue engineering and MACI procedures87,88.  
1.4 In Vitro Chondrogenesis of MSCs Resembles Endochondral Ossification 
Despite all recent advances, cartilage tissues engineered from MSCs still cannot fully 
recapitulate the composition or mechanical properties of native articular cartilage89,90,91. When 
growth factors such as TGF-β, IGFs, and BMPs are used to induce chondrogenesis of MSCs, they 
continue to differentiate down the path of endochondral ossification (Figure 1-3)92,93. During limb 
development, initial chondrogenesis and subsequent endochondral ossification are a multiple-step 
process including mesenchymal condensation, early chondrogenesis, proliferation, hypertrophic 
maturation, calcification, and eventual invasion of blood vessels and bone-forming cells94. After 
committing to the chondrogenic phenotype, characterized by production of aggrecan and type II 
collagen, MSC-derived chondrocytes (MdChs) also express markers that are indicative of 
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continuing maturation (chondrocyte hypertrophy)95. These maturing chondrocytes stop producing 
and start degrading aggrecan and type II collagen, disrupting the ECM structure that is needed for 
the mechanical integrity of newly formed cartilage tissue. 
 
Figure 1-3. H&E staining of articular and growth plate cartilage. 
During endochondral ossification, hypertrophy-induced ECM remodeling is a critical step 
that prepares for the subsequent mineral deposition within cartilaginous matrix96. During this 
process, matrix metalloproteinase-13 (MMP13) is secreted by hypertrophic chondrocytes97. As a 
member of a larger family of MMPs, MMP13 can degrade both aggrecan 98 and type II collagen99.  
Specifically, it cleaves aggrecan at the Asn341-Phe342 bond in the IGD, releasing the domains that 
were bound by chondroitin-sulfates100. The loss of these negatively-charged molecules directly 
reduces the compressive strength of cartilage tissue8. MMP13 also has a high affinity to type II 
collagen and breaks the molecule into a ¾ and a ¼ fragments101, disrupting the structure of collagen 
fibrils that contribute to the tensile strength of articular cartilage. Similarly, hypertrophy of MdChs 
induces the degradation of aggrecan and type II collagen, compromising the mechanical strengths 
of engineered cartilage tissues102,103.  Therefore, inhibition of hypertrophy in MdChs and the 
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maturation-associated matrix degradation associated with this phenotype would 
significantly improve the application of MSCs in cartilage tissue engineering. 
Many molecular and biophysical cues stimulate chondrocyte hypertrophy, including 
IHH104, TGF-β105, Wnt/β-catenin106, Smad107, calcium108, and reactive oxygen species109. These 
stimuli all modulate the activity of master regulator of chondrocyte hypertrophy, the transcription 
factor RUNX2 (runt-related transcription factor 2) RUNX2106,110,111. RUNX2 upregulates 
COL10a1112,113, MMP13114,115, VEGF116,117 during hypertrophy and terminal differentiation of 
chondrocytes as endochondral ossification progresses. Transgenic mice expressing conditional 
knockout of RUNX2 exhibit impaired endochondral ossification, marked by delayed chondrocyte 
maturation and less absorption of articular cartilage118–120. These findings suggest that targeting 
RUNX2 in chondrogenic cells can increase long-term matrix accumulation by maintaining 
aggrecan and collagen II production and preventing their degradation.  
1.5 RNAi-based Treatments in Cartilage Tissue Engineering 
Gene silencing via RNA interference (RNAi) can be used to directly target intracellular 
regulators of chondrocyte phenotype, such as RUNX2. RNAi of a gene induces its loss of function 
by stimulating targeted degradation or suppressing the translation of its mRNAs121,122. Three types 
of RNA molecules are commonly used to facilitate RNAi; they include the naturally occurring 
short interfering RNAs (siRNAs), microRNAs (miRNAs), and the artificial short hairpin RNAs 
(shRNAs). Compared to the forced overexpression of a transgene, the gene silencing approach 
allows precise targeting of a therapeutic pathway by mimicking regulatory machineries that 
naturally exist in cells, therefore exerting less stress on cells123,124,125. The clinical potential of 
RNAi techniques has been heavily investigated in many diseases areas, such as cancer, viral 
infections, inflammatory disorders, and more than 40 RNAi clinical trial programs have been 
completed or are ongoing (https://www.clinicaltrials.gov)126. 
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Combining the power of RNAi with our increasing knowledge of chondrocyte regulation, 
different research groups have demonstrated the feasibility of silencing key regulators to promote 
chondrogenesis of MSCs and inhibiting hypertrophy that is undesirable for cartilage tissue 
engineering. For example, siRNAs targeting ERK5 and ERK1/2 promote chondrogenic 
differentiation of adult human MSCs127 while ones against RUNX2 suppress hypertrophy in 
MdChs128,129. Non-viral or viral systems are required to deliver RNAi across the cell membrane as 
chondrocytes/MSCs do not uptake naked RNA molecules spontaneously. Different non-viral 
approaches based on lipids130,131, electroporation132, nanoparticles133,129, quantum dots128,134, and 
extracellular vesicles135 have been developed to deliver siRNAs and miRNAs. However, silencing 
from these non-viral methods tends to be transient and, therefore, achievement of lasting effects 
requires sustained delivery of new RNA molecules136. Continuous delivery of RNA could be 
challenging if the silencing of a gene is needed during the entire life cycle of the implanted 
neotissue. In contrast, viral vectors can introduce stable integration of shRNAs and provide long-
term inhibition of the targeted genes137,138. The recombinant vectors intended for both adeno-
associated virus (AAV) and lentiviral virus (LV) can efficiently transduce chondrocytes as well as 
MSCs139–142. LV-delivered shRNAs can also be passed onto daughter cells during mitosis.  
1.6 Design of Lentiviral-based shRNA Vector 
Commonly used lentiviral vectors are based on the second- or third-generation lentiviral 
vectors due to safety considerations. To reduce the likelihood of generating replication-competent 
viruses, current plasmid vectors only contain a promoter, the sequence of interest that needs to be 
expressed, and essential cis-acting elements that are required for viral packaging, reverse 
transcription, and genome integration (Figure 1-4a). Other components required for viral 
replication are usually delivered to host cells in separate plasmids143. For the purpose of this thesis, 
we will focus on the design of the promoter and shRNA elements within the vector plasmid.  
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shRNA is a synthetic RNA molecule that can be transcribed by endogenous machinery. 
After transcription, the precursor RNA folds into a hairpin structure because the molecule contains 
a siRNA sequence and its reverse complement sequence, which are separated by a short loop 
region (Figure 1-4b). The formed shRNAs can be further processed into mature siRNAs to induce 
silencing based on their targeted sequences144. This type of shRNAs (referred here as basic 
shRNAs) are often expressed using Pol III promoter such as U6 and H1145,146147. While these strong 
promoters can generate a large amount of shRNAs to induce a high level of silencing, this type of 
RNAi has also been reported to cause high cell toxicity and animal death148.  To improve shRNA-
based gene silencing, Zeng and colleagues discovered that precursor miRNAs can be used to 
process artificial shRNAs from a random long mRNA transcript (Figure 1-4c)149,150. This finding 
allows shRNAs to be processed by naturally occurring miRNA pathways, mitigating toxicity 
induced by basic shRNAs151. Moreover, the miRNA-based shRNAs can be expressed by Pol II 
promoters152,153, allowing the possibility of using mammalian promoters, especially tissue-specific 
ones, to control RNAi.  
In mammalian cells, the promoter, located at the 5' end of the transcription start site of each 
gene, directs the initiation of transcription by polymerase. These promoters can be separated into 
two classes: “broad” and “sharp”154. Defined by their patterns of transcription start sites (TSSs), 
broad promoters can initiate transcription over a dispersed genetic region (~100bp) while sharp 
promoters maintain their TSSs at a focused, narrow region (less than a few nucleotides)155. A 
recent genome-wide analysis revealed that the CpG-rich broad promoters represent the majority 
of mammalian promoters156, controlling the embryonic and housekeeping genes157,158. In 
contrast, the sharp promoters usually contain a highly conserved TATA-box154. Although they 
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only represent less than 12% of mammalian promoters157, this type of promoter commonly 
controls the tissue-specific gene expression156. 
 
Figure 1-4. Lentiviral-based shRNA system. (a) Diagram of a lentiviral vector. Processing of (b) basic shRNA and 
(c) microRNA-based shRNA. 
  Because tissue specific promoters initiate transcription in only certain cell types, they can 
target miRNA-based shRNA expression in cells of interest while restricting unwanted silencing in 
non-target cells. These promoters could lead to more confined, persistent silencing, fewer side 
effects, and a lower chance of causing cancers compared to the nonspecific, constitutively active 
promoters159–161.Typically, tissue-specific promoters are derived from marker genes of a certain 
cell type. For example, promoters of aggrecan and osteocalcin are used to target 
chondrocytes120and osteoblasts162,163, respectively. The increasing number of available tissue-
specific promoters have made it very convenient to induce gene silencing in various types of cells. 
Furthermore, findings from several bioinformatics studies have predicted that partial promoter 
sequences can recapitulate tissue specificity even though they do not contain all the regulatory 
elements that exist within the full-length endogenous promoters154,164,165. Therefore, truncated 
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tissue-specific promoters can be synthesized to reduce the size of viral vectors and improve 
packaging efficiency166,167.  
1.7 Project Goal and Hypothesis 
The overall goal of this project is to develop a gene circuit that can inhibit the maturation 
of MSC-derived chondrocytes in a self-sufficient manner as they progress to hypertrophy and 
enhance their accumulation of cartilaginous ECM. We also aim to use the design of such a gene 
circuit as proof-of-concept to demonstrate the feasibility of integrating artificial regulatory 
machinery into mammalian cells to modulate their behavior and optimize tissue engineering 
outcomes. Here, we propose a lentiviral vector that aims to inhibit chondrocyte hypertrophy and 
increase accrual of cartilage matrix via RNAi of Runx2 under the control of a synthetic Col10a1-
like promoter (Figure 1-5). By completing the engineering design cycle, we also intend to 
establish a design-test platform that could help streamline the creation of new gene circuits that 
employ novel tissue-specific promoters or target other regulatory pathways. We hypothesize that 
1) RNAi of Runx2 can enhance matrix accumulation by chondroprogenitor cells by 
inhibiting matrix-degrading enzymes; 2) synthetic cis promoters containing single or 
multiple copies of cis-enhancers and the Col10a1 basal promoter can recapitulate the tissue-
specificity of endogenous Col10a1 promoter and induce RUNX silencing exclusively in 
hypertrophic chondrocytes; and 3) cis-based, RUNX2-silencing gene circuits can improve 
accrual of articular cartilage-specific matrix by MSC-derived chondrocytes via tunable 
negative-feedback regulation of intracellular RUNX2 activity.  
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Figure 1-5. Design of self-regulatory Col10a1-shRunx2 gene circuit. 
1.8 Specific Aims 
Specific Aim 1: Evaluate the effects of RUNX2 silencing at different stages of chondrocyte 
maturation using monolayer ATDC5 model. 
 RUNX2 is suggested to be involved at different stages of chondrocyte development, 
therefore it is important to understand how loss of its function impacts accumulation of matrix 
during chondrogenesis. In this aim, we will first characterize sequential progression from early to 
late chondrogenesis in the monolayer ATDC5 model. Using Tet-on/doxycycline lentiviral system, 
we will create an inducible ATDC5 model that allows flexible induction of RNA interference of 
Runx2. By suppressing the translation of RUNX2 at different phases of chondrocyte differentiation, 
we will evaluate cellular responses, the progression of chondrogenesis, as well as the final accrual 
of sGAG-rich matrix.  Results from this aim will be used to validate the potential of RUNX2 
silencing to inhibit maturation-associated matrix loss.   
Specific Aim 2: Investigate chondrogenic response to phosphate during early and late 
chondrogenesis in both monolayer (2D) and pellet (3D) ATDC5 models. 
This aim will compare chondrogenic differentiation of ATDC5 cells between monolayer 
(2D) and (3D) cultures. To further understand how these two systems respond to the hypertrophy 
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stimuli168, we will perturb differentiation in both models with phosphate at different stages of 
chondrogenesis, monitor cellular responses, and quantify the accumulation of sGAG-rich matrix 
and mineral deposits. In addition, we will also investigate if phosphate can be used to expedite 
chondrogenic maturation in both models 
Specific Aim 3: Study the matrix accumulation during chondrogenic differentiation of ATDC5 
cells and murine MSCs under the control of the self-regulatory cis-RUNX2 silencing gene circuits. 
 In this specific aim, we will first synthesize Col10a1-like cis promoters by assembling the 
Col10a1 basal promoter and different copies of cis-enhancer, and we then will validate the tissue-
specificity of these promoters in the 2D ATDC5 model. Using the verified cis promoters, we will 
assemble cis-shRunx2 gene circuits and characterize their activity during chondrogenic 
differentiation using a luciferase reporter in the 2D ATDC5 model. Different versions of cis-
shRunx2 gene circuits will be evaluated under the normal chondrogenic condition and phosphate-
stimulated environment. Finally, we will examine how different RUNX2 silencing gene circuits 
affect accumulation of matrix during long-term ATDC5 (5-weeek) and murine MSC (8-weeek) 
pellet cultures. 
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Chapter 2 Phenotype-dependent Effects of RUNX2 Silencing During Chondrogenesis 
2.1 Introduction 
Defects in articular cartilage occur frequently after joint injuries; however, the lack of 
blood supply hinders the natural healing of these damages due to the limited access to progenitor 
cells and nutrients1. Unrepaired defects lead to abnormal joint loading, which further induces 
deterioration of remaining cartilage tissues2–4.  Clinical surgical techniques for cartilage repair, 
such as microfracture and osteochondral transplantation are not designed to form new hyaline 
cartilage and therefore do not restore the long-term function of injured tissues5,6. Currently, all 
FDA approved cell-based cartilage products require articular chondrocytes, which have very 
limited availability and poor capacity to proliferate7. Furthermore, repair strategies using 
autologous articular chondrocytes often cause donor site morbidity and require multiple invasive 
surgeries8,9.  
Mesenchymal stem cells (MSCs) have been extensively studied as an alternative cell 
source to regenerate articular cartilage due to the fact that they can be harvested from numerous 
tissues, have a higher potential for in vitro expansion, and can be induced to differentiate into 
chondrocytes10,11. Despite these advantages, chondrogenic induction of MSCs in vitro yields a 
phenotype indicative of the late phases of endochondral ossification found in growth cartilage, 
which include hypertrophic maturation and matrix calcification12–14. Specifically, MSC-derived 
chondrocytes (MdChs) express hypertrophy markers  such as COL10a1 and MMP1315. 
Consequently, existing aggrecan and type II collagen are degraded in the cartilaginous matrix16,17.  
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RUNX2 (Runt-related transcription factor 2) has been shown to drive the chondrocytes to 
the pre-hypertrophic phenotype by directly controlling the transcription of both COL10a1 and 
MMP1318–21. This transcription factor also upregulates several other proteins that modify the 
existing cartilage ECM and contribute to the progression of endochondral ossification22–24. 
Because of the essential role of RUNX2 in chondrocyte hypertrophy, targeting its activity could 
be an effective strategy to prevent maturation-associated matrix degradation and improve MSC-
based cartilage repair.  
To enhance the accumulation of aggrecan and type II collagen in MSC-based cartilage 
products, growth factors are frequently used to either encourage the production or inhibit the 
degradation of these structural macromolecules25–30. However, the response of the cells to growth 
factor supplementation is dependent on the expression of specific receptors and the maturation 
stage of the target cells31. For example, TGF-β (transforming growth factor-β), when used to 
induce early chondrogenesis of MSCs in vitro25,26, upregulates aggrecan and collagen II by binding 
ALK-5 (activin receptor-like kinase 5)32. Nevertheless, TGF-β can also upregulate RUNX2 
through binding of the ALK-1 receptor, contributing to chondrocyte hypertrophy33. Due to the 
inherent heterogeneity in stem cell populations, the same medium recipe might induce variable 
cell responses depending on the maturation stage of chondrogenic cell populations. The 
dependence on maturation stage has also been demonstrated in recent studies using PTHrP 
(parathyroid hormone-related peptide) to inhibit hypertrophy of human MdChs. Recently, Li et al. 
have shown that PTHrP can suppress RUNX2 expression in human MSCs at both the mRNA and 
protein levels34–36. However, supplementation of PTHrP to undifferentiated MSC cultures 
inhibited TGFβ-induced chondrogenesis36. These findings suggest that RUNX2 is involved at 
different stages of chondrocyte development. This has been confirmed in later studies that 
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demonstrate RUNX2 expression in mesenchymal condensation prior to early chondrogenesis37–39. 
Based on this data, direct manipulation of intracellular pathways that regulate chondrocyte 
phenotype through the RUNX2 pathway can bypass the need for specific receptor-ligand 
interactions to control the phenotype of chondrogenic cells and improve accrual of cartilage 
structural macromolecules in engineered tissues. 
 To determine if inhibition of RUNX2 can enhance matrix accumulation during 
chondrogenesis, we created a doxycycline-inducible lentiviral system to induce RNA interference 
(RNAi) of Runx2 in the murine pre-chondrogenic cell line ATDC5. ATDC5 cultures are an 
effective model system to recapitulate the different phases of early and late chondrogenesis40–42. 
At confluence, the addition of insulin breaks contact inhibition and stimulates pre-chondrogenic 
proliferation, followed by early chondrogenesis and then chondrocyte hypertrophy. Using this 
model system we investigated the effects of suppression of RUNX2 translation at different stages 
of chondrocyte maturation. We found that induction of RUNX2 silencing in undifferentiated 
chondroprogenitors inhibits pre-chondrogenic proliferation that is required for their further 
differentiation into chondrocytes. After this proliferation phase, RNAi of Runx2 no longer 
interferes with early chondrogenesis, instead it downregulates expression of maturation markers 
(Col10a1 and Mmp13) and improves the accumulation of sGAG-rich matrix. 
2.2 Methods  
2.2.1 Vector and Virus Production 
The Tet-on inducible system was modified from the pINDUCER plasmid originally 
developed by Meerbrey et al43.  Different shRNA sequences of Runx2 were selected from the 
Hannon-Elledge library (RNAi Codex http://cancan.cshl.edu/cgi-bin/Codex/Codex.cgi), and PCR 
amplified using primers 5’-CAGAAGGCTCGAGAAGGTATATGCTGTTGACAGTGAG-CG 
and 5’-CTAAAGTAGCCCCTTGAATTCCGAGGCAGTAGGCA. The PCR product was 
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digested with EcoRI and XhoI, and then ligated to pINDUCER13 vector that was also digested 
with EcoRI and XhoI. To remove the luciferase cDNA from Tet-on-Luc-mir30-shRunx2, mir30-
shRunx2 was PCR amplified using primers 5’-GATCCAGCCTACCGGTAAGCCTTGTTAAG-
TGCTCGC and 5’-CTAAAGTAGCCCCTTGAATTCCGAGGCAGTAGGCA. The PCR product 
was digested with EcoRI and AgeI, and then ligated to Tet-on-Luc-mir30-shRunx2 that was also 
digested with EcoRI and AgeI. Correct cloning of Tet-on shRunx2 (included mir30) was confirmed 
by Sanger sequencing at UM Sequencing core, and lentiviral supernatant of the correct plasmid 
vectors was produced at UM Vector Core. Viruses containing a scrambled shRunx2 sequence was 
synthesized similarly. 
2.2.2 Chondrogenic Cell Cultures 
ATDC5 cells (Sigma) were maintained in DMEM/F12 (Life Technologies) supplemented 
with 5% FBS (Life Technologies) and 1% Antibiotic-Antimycotic (Life Technologies). 
Chondrogenesis of ATDC5 cells was induced with chondrogenic differentiation medium (ITS+) 
consisting of the growth medium supplemented with 1% ITS+ Premix (Corning) and 50 µg/ml 
ascorbate acid-2-phosphate (Sigma).  
Four days prior to chondrogenic induction, cells were seeded at the density of 10,000 
cells/cm2 in multiple well plates. When cells reached 100% confluence (D0), chondrogenesis was 
initiated by replacing the growth medium with differentiation medium. Cultures were fed with 
fresh medium every other day and maintained up to 28 days. 
Cell Transduction and Induction of Silencing 
Proliferating ATDC5 cells were transduced [multiplicity of infection (MOI) = 1] with 
lentiviral supernatant of Tet-on shRunx2 or scramble vectors. Polyclonal populations of cells stably 
expressing the inducible shRunx2 were obtained by puromycin selection. Transduced cells that 
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survived puromycin selection were chondrogenically induced in the absence or presence of 0.5 
µg/ml doxycycline (Dox) during the selected time periods.  
2.2.3 Biochemical Analysis  
Cartilage-specific matrix production was measured by the 1,9-dimethylmethylene blue 
(DMMB) assay as previously described44. Both monolayer cell tissues and pellets were digested 
with 1 mg/ml proteinase K in 0.1M ammonium acetate at 50°C for 16 hours. Digested samples 
were mixed with DMMB dye (pH 1.5) at a ratio of 1:20, and the sGAG content of the samples 
were determined by comparing the ratio of 525 nm to 595 nm readings to the standard curve 
derived from shark chondroitin sulfate. Measured sGAG content of each sample was normalized 
by its DNA content using Hoechst 33258 dye (Sigma) as previously described45. 
2.2.4 Gene expression Analysis 
Total RNA of each sample was extracted using TRI Reagent® RT (Molecular Research 
Center). For pellet culture, five pellets were combined and homogenized in the same reagent using 
the Micro Tube Homogenizer. Equal amounts of extracted RNA were reverse-transcribed into 
cDNA using High-Capacity cDNA Reverse Transcription Kit (Life Technologies). Synthesized 
cDNA was amplified using Fast SYBR® Green Master Mix (Life Technologies) on Applied 
Biosystems® 7500 Fast platform. The mean cycle threshold of the housekeeping genes ( hkCt ) 
Hprt and Ppia46 were used to calculate the fold change in transcript levels compared to day 0 
samples using the Ct  method. Relative expression levels were calculated as 2 Ctx  , in 
which Ct E C    , 
exp hkE Ct Ct    at the time-point of interest, and exp hkC Ct Ct    at 
day 0. The forward and reverse primer sequences are listed in Table 2-1.  
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Table 2-1. The sequences of primers used 
 
 
2.2.5 Histological Analysis 
Monolayer cultures were washed twice with PBS and fixed in 70% ethanol at room 
temperature for one hour. Proteoglycan accumulation in monolayer tissues was evaluated by 
staining the sectioned tissue with 3% Alcian blue dye (Poly Scientific) at 4℃ for 16 hours. Stained 
tissues were washed three times with PBS and imaged using bright field microscopy.  
2.2.6 Western Blot Analysis 
Cultured cells were lyzed in RIPA Lysis and Extraction Buffer (Thermo Scientific) 
supplemented with protease inhibitor cocktail (Sigma), rotated at 4 °C for one hour, and 
centrifuged at 12,000g for 10 minutes to remove cellular debris. Total protein content within each 
sample was determined with the Pierce BCA Protein Assay Kit (Pierce). Protein (5-15 𝜇g) was 
separated on a 10% NuPAGE Bis-Tris Protein Gel and then transferred to a polyvinylidene 
difluoride membranes (Millipore). Membranes were blocked with Tris-buffered saline-Tween 20 
(TBS-T, 0.1% Tween 20) and 5% BSA for 1 h at room temperature. Following blocking, 
membranes were incubated in TBS-T, 0.1% Tween 20 and 5% BSA overnight at 4 °C with rabbit 
anti-Runx2 antibody (Cell Signaling Technology, D1H7, 1:2000) and rabbit anti-β-actin antibody 
(Abcam, 119716, 1:5000). Positive staining was visualized using the LiCor C-DiGit 
chemiluminescence and quantified using the LiCor Image Studio.  
2.2.7 Statistical Analysis 
Gene
Acan Forward CGCCACTTTCATGACCGAGA Reverse CAAATTGCAGAGAGTGTCCGT
Adamts4 Forward ATGGCCTCAATCCATCCCAG Reverse AAGCAGGGTTGGAATCTTTGC
Adamts5 Forward GGAGCGAGGCCATTTACAAC Reverse CGTAGACAAGGTAGCCCACTTT
Col2a1 Forward ACGAGGCAGACAGTACCTTG Reverse AGTAGTCTCCGCTCTTCCACT
Col10a1 Forward CCAAACGCCCACAGGCATAA Reverse TGCCTTGTTCTCCTCTTACTGG
Hprt Forward CTGGTGAAAAGGACCTCTCGAA Reverse CTGAAGTACTCATTATAGTCAAGGGCAT
Ppia Forward CGCGTCTCCTTCGAGCTGTTTG Reverse TGTAAAGTCACCACCCTGGCACAT
Mmp13 Forward GGAGCCCTGATGTTTCCCAT Reverse GTCTTCATCGCCTGGACCATA
Primer Sequences (5'→3')Primer Sequences (5'→3')
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Statistical analysis was performed using GraphPad Prism software. All comparisons over 
multiple time points were analyzed by two-way ANOVA with Tukey’s multiple comparison 
method. Comparisons in experiment with a single time point were analyzed by one-way ANOVA 
followed by Sidak correction. Significant difference is indicated by * P<0.05, ** P<0.01, 
***P<0.001, ****P<0.0001. All error bars indicate the standard error of the mean (s.e.m.).   
2.3 Results 
2.3.1 RUNX2 Expression in the Monolayer ATDC5 Chondrogenic Model  
We first characterized the different phases of chondrocyte development in the ATDC5 cells 
in monolayer cultures. At confluence, ATDC5 cells were chondrogenically induced by the 
supplementation of ITS+ and AA2P to the growth medium. After 24 hours, secondary proliferation 
post contact-inhibition occurred in response to the addition of ITS+, reflected by 1.8-fold increase 
in the total amount of DNA in each culture (Figure 2-1a). Proliferation of the cells plateaued at 
day 5, where it was 2.9 times higher than that of day 0. Cartilaginous nodules began to appear on 
day 7, as indicated by the positive staining of Alcian blue dye (Figure 2-1b). These Alcian blue-
positive areas continued to grow within the monolayer from day 7 to day 21, accompanied by the 
darker staining within each nodule at the later time points. The accumulation of sGAG-rich matrix 
was further quantified using DMMB assay (Figure 2-1c). Upregulation of Acan and Col2a1 gene 
expression coincided with the initial appearance of the cartilaginous nodules, further confirming 
early chondrogenesis. Both peaked at day 10 (Figure 2-1d). RUNX2 expression was transiently 
downregulated after the initial exposure to the chondrogenic stimuli, shown by the minimal 
detection from western blotting (Figure 2-1e). However, differentiating cells started to express 
RUNX2 protein again at day 7 and continued to upregulate it until day 21. The mRNA level of 
Col10a1 started to elevate at day 10 and reached to the maximum level at day 21.  
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Figure 2-1. Early and late chondrogenesis in monolayer ATDC5 culture. (a) Fold change (relative to day 0) in 
DNA content over 21 days of differentiation (n=3). (b) Alcian blue staining at day 0, 7, 14, and 21 to show 
accumulation of sGAG-rich matrix (4× magnification). (c) Fold change (relative to day 0) in sGAG accumulation 
normalized to DNA content (n≥8, three independent experiments). (d) Quantification of mRNA expression (relative 
to day 0 and the housekeeping genes Hprt and Ppia) of early (Acan and Col2a1) and late (Col10a1) chondrogenic 
markers (n≥5, two independent experiments). (e) Quantified RUNX2 protein expression (%, relative to β-actin) over 
f 
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21 days of differentiation. All data represented as mean ± s.e.m. (f) the time-course of chondrocyte maturation in 
monolayer cultures of ATDC5 cells. 
2.3.2 Constitutively Silencing RUNX2 Inhibits Chondrogenesis 
In cultures treated with Dox from day 0, RUNX2 protein was depleted in cells expressing inducible 
shRunx2 by day 7 (Figure 2-2a). There was also no significant proliferation in these cultures from 
day 0 (Figure 2-2b). There was also no detectable amounts of matrix accumulation or expression 
of mRNA for Acan and Col2a1 by day 14, while the scramble controls had successfully formed 
many Alcian blue-positive nodules (Figure 2-2c-e). In contrast, in the absence of Dox, the 
formation of the sGAG-rich nodules and upregulation of early chondrogenic markers were 
observed in both inducible shRunx2 and scramble cultures.  
 
Figure 2-2. Effects of constitutively active RUNX2 silencing on early chondrogenesis. ATDC5 cells expressing 
Tet-on shRunx2/scramble differentiated in the absence (-) or presence (+) of 0.5 µg/ml doxycycline for 14 days. (a) 
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Western blot analysis of RUNX2 and β-actin at day 7 and 14. (b) Fold change (relative to day 0) in DNA content at 
day 7 (different groups at day 7 were compared against day 0). (c) Alcian blue staining, (d) sGAG accumulation 
normalized to DNA content, (e) quantification of mRNA expression (relative to Hprt and Ppia) of Acan and Col2a1 
at day 14. Polyclonal populations were established by combining selected cells from two independent transduction 
experiments (two viral batches, n=3). All data represented as mean ± s.e.m. Significant difference is indicated by * 
P<0.05 and ** P<0.01 by two-way ANOVA with Tukey’s multiple comparison method.        
2.3.3 Delayed RUNX2 Silencing Enhances Matrix Accumulation During Chondrogenesis 
 
Figure 2-3. Effects of RUNX2 silencing at different maturation stages of chondrogenesis. Fold change (%, relative 
to D14 No Dox controls) in sGAG accumulation normalized to DNA content at day 14 and 28. Data represented as 
mean ± s.e.m. Polyclonal populations were established by combining selected cells from two independent transduction 
experiments (two viral batches, n=3). Significant difference between Tet-on shRunx2 and scramble groups at each 
time point is indicated by ***P<0.001 and ****P<0.0001 by two-way ANOVA with Tukey’s multiple comparison 
method.  
To determine if the RUNX2 silencing-induced suppression of matrix accumulation 
continued after pre-chondrogenic proliferation, Dox treatment was started at the onset of specific 
maturation stages (days 4, 7, 14, or 21; Figure 2-1f) and continued through day 28. When RUNX2 
was inhibited just after the initial phase of proliferation (day 4), cells expressing Tet-on shRunx2 
accumulated 1.9 times higher amount of matrix by day 28 when compared to that of the scramble 
controls. A similar positive effect on matrix accumulation was also observed when inhibition was 
initiated at the start of RUNX2 protein upregulation (day 7) and maximum Col10a1 gene 
expression (day 14), resulting in a 2.19- and a 1.75-fold increase by day 28, respectively (Figure 
2-3).  
Although the addition of Dox from day 7 decreased the level of RUNX2 protein in Tet-on 
shRunx2 cells, complete depletion did not occur in response to the concentration of Dox that was 
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used (Figure 2-4a). At both day 14 and 28, the downregulated protein expression of RUNX2 in 
the shRunx2 cells correlated with lower mRNA levels of Col10a1 compared to the scramble 
controls (Figure 2-4b). Interestingly, Dox treatment from day 7 also seemed to result in significant 
upregulation of Acan and Col2a1 genes in the scramble cells at day 14 when compared to the non-
treated scramble controls. However, the addition of Dox did not change expression levels of these 
two early chondrogenic markers in shRunx2 cells.  
 
Figure 2-4. Effects of 7-day delayed RUNX2 silencing on chondrogenesis. Dox (0.5 µg/ml) was supplemented 
from day 7 during the differentiation of ATDC5 cells expressing Tet-on shRunx2/scramble until day 28. (a) Western 
blot analysis of RUNX2 and β-actin at day 14 and 28. (b) Quantification of mRNA expression (relative to Hprt and 
Ppia) of Col10a1, Acan and Col2a1 at day 14 and 28. Polyclonal populations were established by combining selected 
cells from two independent transduction experiments (two viral batches, n=3). All data represented as mean ± s.e.m. 
Significant difference is indicated by * P<0.05, ** P<0.01, ***P<0.001, ****P<0.0001 by two-way ANOVA with 
Tukey’s multiple comparison method.  
2.3.4 Delayed RUNX2 Silencing Suppresses Mmp13 Transcription During Hypertrophy       
To further examine the effects of delayed RUNX2 suppression on the gene expression of 
matrix-degrading enzymes, we also measured the mRNA levels of Mmp13, Adamts4 (aggrecanase-
1), and Adamts5 (aggrecanase-2) in 4-, 7-, and 14-day delayed silencing groups after hypertrophy 
occurred (day 21 and 28). Dox treatment from day 7 and 14 of Tet-on shRunx2 cells significantly 
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lowered mRNA levels of Mmp13 at both day 21 and 28 while their corresponding scramble 
controls exhibited little change (Figure 2-5a). Although Dox treatment from day 4 also 
downregulated Mmp13 in shRunx2 cells, a similar decrease was observed in scramble cultures by 
day 14. In contrast to Mmp13, Adamts4 expression was not affected by Dox induction throughout 
the culture period (Figure 2-5b). Interestingly, addition of Dox seemed to broadly increase the 
mRNA levels of Adamts5 in both shRunx2 and scramble cells compared to non-treated ones 
(statistical significance was found in all treated groups, not labeled). However, the only significant 
difference was observed between shRunx2 and scramble cultures at day 28 in the 4-day delayed 
Dox condition (Figure 2-5c). Together, these results suggest RUNX2 silencing reduces the 
transcription of Mmp13 but not Adamts4 or Adamts5 during chondrocyte hypertrophy.  
 
Figure 2-5. Effects of delayed RUNX2 silencing on gene expression of matrix degrading enzymes. Quantification 
of mRNA expression (relative to Hprt and Ppia) of (a) Mmp13, (b) Adamts4, and (c) Adamts5 at day 21 and 28. 
Polyclonal populations were established by combining selected cells from two independent transduction experiments 
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(two viral batches, n=3). All data represented as mean ± s.e.m. Significant difference is indicated by * P<0.05, ** 
P<0.01, ***P<0.001, ****P<0.0001 by two-way ANOVA with Tukey’s multiple comparison method. 
2.4 Discussion & Conclusion 
In this chapter, we demonstrate that the loss of RUNX2 function during the chondrogenesis of 
mesenchymal progenitors can elicit distinct cellular responses at different stages of differentiation. 
Using a 2D ATDC5 model with inducible shRunx2 expression, we show that RNAi of Runx2 in 
the undifferentiated cells inhibits mesenchymal proliferation and differentiation into chondrocytes. 
However, induced expression of shRunx2 after the pre-chondrogenic proliferation phase or early 
chondrogenesis enhances the accumulation of cartilaginous matrix. We also observed that RUNX2 
silencing decreases the transcription of Mmp13 but does not affect the gene expression of Adamts4 
or Adamts5 during hypertrophy. In addition, RUNX2 silencing during early chondrogenesis and 
pre-hypertrophy may also moderately downregulate the gene expression of Acan and Col2a1. Thus, 
maximizing the accumulation of cartilaginous matrix via RNAi of Runx2 requires balancing the 
inhibition of degradation and repression of production by optimizing the timing and dosing of 
shRunx2 expression.   
Here, our results suggest that RNAi of Runx2 in undifferentiated progenitor cells inhibits 
the proliferation required for in vitro chondrogenesis. Unlike the well-established role of RUNX2 
in driving chondrocyte maturation, its involvement in early events of chondrogenesis remains 
unclear. Progenitor cells within the prechondrogenic condensation first proliferate before 
committing to chondrogenic differentiation47–49. Runx2 expression has been detected within these 
condensations37–39. Recently, Dexheimer et al. showed that this transient phase of proliferation is 
required for in vitro chondrogenesis of human MSCs after cells are condensed into a micromass 
pellet50. In our study, when chondrogenesis is induced in confluent monolayer ATDC5 cultures, 
the differentiation initiates with a similar phase of proliferation that overrides the contact inhibition 
during the first 4 days, which does not occur under the RNAi of Runx2. In accordance with our 
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observations, Akiyama et al. also showed that introduction of the dominant negative form of 
RUNX2 in ATDC5 cells inhibits the cellular condensation and subsequent chondrogenic 
differentiation51. Similar suppression of chondrogenesis is also observed when Zfp521, an inhibitor 
of RUNX2, is overexpressed in ADTC5 cells52. However, it is worth noting that Runx2-/- mice do 
form cartilaginous skeleton53,54, suggesting that the in vivo cartilage formation involves different 
signaling pathways from those required for in vitro chondrogenesis. Nonetheless, constitutively 
active RNAi of Runx2 is not suitable for MSC-based cartilage tissue engineering. 
Our results also show that delayed RUNX2 silencing in chondroprogenitors after the pre-
chondrogenic proliferation phase does not interfere with their further progression to early 
chondrogenesis; instead it increases the amount of matrix accumulated by these differentiated 
chondrocytes, supporting our original hypothesis. As chondrogenesis proceeds, the role of RUNX2 
changes55. After pre-chondrogenic proliferation in vivo, Nkx3.2-mediated repression of Runx2 
promotes early chondrogenesis by activating Sox956. These findings are analogous to our 
observation of the downregulation of RUNX2 after chondrogenic induction in ATDC5 cells. They 
also likely explain why loss of RUNX2 function after day 4 no longer blocks chondrogenesis in 
ATDC5 cells. As in growth plate chondrocytes57, the low protein expression of RUNX2 is not 
permanent in the ATDC5 model. Quickly following the upregulation of Col2a1 and Acan, protein 
expression of RUNX2 elevated and drove differentiated chondrocytes to the pre-hypertrophic and 
then hypertrophic phenotypes. As expected, induced RUNX2 silencing at this stage of chondrocyte 
maturation decreased mRNA levels of both Col10a1 and Mmp13. MMP13 can degrade both 
aggrecan16 and type II collagen17 and downregulation of Mmp13 due to the loss of RUNX2 
function has been reported to reduce the breakdown of these structural molecules in Runx2 
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deficient mice58. This is consistent with our observation that RUNX2 silencing leads to an 
increased level of matrix accumulation after control groups undergo hypertrophy. 
Importantly, results from this chapter indicate that RNAi of Runx2 in chondrocytes that are 
transitioning to the pre-hypertrophic phenotype maximizes the accumulation of matrix since it is 
a net function of production and turnover. While RUNX2 silencing is desirable for reducing 
MMP13-mediated matrix degradation, we also noticed that it seems to downregulate the gene 
expression of Acan and Col2a1 at varying levels. While the relationship RUNX2 activity and 
transcription of Acan and Col2a1 remains to be clarified, RUNX2, together with RUNX1, has been 
shown to induce the expression of Sox5 and Sox6, which further control the induction of Col2a159. 
Additionally, RUNX2 is a common target of TGF-β1 and BMP-2, both of which are frequently 
used to induce chondrogenesis of MSCs60. These studies, together with our results, suggest that 
Runx2 activity may also contribute to the production of aggrecan and type II collagen. Although 
we cannot easily decouple the regulation of early chondrogenic markers and matrix-degrading 
enzymes by RUNX2, the different expression profiles of early and late chondrogenic markers 
allow us to optimize the temporal activation of shRunx2 expression to maximize the accumulation 
of matrix during chondrogenesis. Identifying such an optimal time is critical because the premature 
loss of RUNX2 function reduces the production of aggrecan and type II collagen while the belated 
silencing permits uncontrolled matrix degradation. 
 Although exogenous cues can be used to control the temporal induction of RNAi as well 
as levels of RUNX2 suppression, the application potential of this type of RUNX2 silencing is 
limited for several reasons. First, the continuous suppression of RUNX2 translation would require 
sustained delivery of doxycycline during the entire life cycle of the implanted cells. Second, the 
outcome of ubiquitous RUNX2 silencing among a heterogeneous population of stem 
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cells/chondrocytes could be suboptimal. In addition, long-term use of doxycycline or other 
inducers might cause cytotoxicity, especially when high levels of RUNX2 silencing is needed. 
These limitations create a need to develop a method that could target the RNAi of Runx2 
exclusively in chondrocytes that are maturing to hypertrophy. Ideally, it should also be able to 
provide self-regulated levels of silencing based on the states of the cells. Finally, observations from 
this chapter resulted only from a 2D chondrogenic environment, which might omit important 
cellular response that can only be observed in a three-dimensional microenvironment.  
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Chapter 3 Phosphate Regulates Chondrogenesis in a Biphasic and Maturation-dependent 
Manner 
This chapter was published in Differentiation in 2017 [95] 
3.1 Introduction 
Understanding the factors regulating chondrogenesis and endochondral ossification is 
important to treating developmental disorders and the cartilaginous diseases, as well as improving 
stem cell-based cartilage tissue regeneration. Dysfunction in chondrocyte proliferation can lead to 
developmental issues, such as achondroplasia1 and hypochondroplasia2. Hypertrophic 
differentiation of chondrocytes, a process that occurs normally during endochondral ossification, 
is associated with pathogenic changes in osteoarthritic articular cartilage3–5. Mesenchymal stem 
cells (MSCs) also express hypertrophic markers after chondrogenic induction in vitro6,7 and in 
vivo8, hindering their clinical application for cartilage tissue regeneration.  
One potent factor that mediates cell fate in chondrocytic cells is inorganic phosphate (Pi). 
Studies in ATDC59–11, primary growth plate12, and limb bud cells13 have established that Pi in the 
range of 2-4mM upregulates collagen type X expression and apoptosis in mature chondrocytes, 
thus, inducing terminal differentiation. The role of Pi as a signaling molecule has also been 
demonstrated in several other cell types14–18, including osteochondral progenitor cells in which it 
induces osteogenic differentiation14,15. Furthermore, many of these cell-mediated activities are 
regulated by other exogenous cues, such as growth factors19–21 and matrix composition13. 
The response to Pi is orchestrated by the activity of phosphatases, such as alkaline 
phosphatase (ALP)22–24, the availability of pyrophosphate (PPi)25,26, and activity of sodium-
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dependent phosphate transporters in skeletal19,27,28 and non-skeletal systems29,30. ALP cleaves PPi 
to release Pi31, and ALP expression in the growth plate progressively increases from being hardly 
detectable in the proliferative zone to higher in the maturing zone, and highest in the hypertrophic 
zones32. Deficiency of ALP activity causes hypophosphatasia, which is a skeletal disease 
associated with diminished or absent hypertrophic zones in the growth plate33. The expression 
profile of sodium-dependent phosphate cotransporter 1 (PiT-1) has been found to be variable 
during endochondral ossification. In vitro, expression levels were found to be highest during the 
early stages of chondrogenesis in the CFK2 chondroprogenitor cell line34 and during the 
proliferative and the early phase of hypertrophy in ATDC5 cells28,35. In vivo, the expression profile 
of PiT-1 has been variable depending on species36. The effects of Pi during terminal differentiation 
require the activity of PiT-119,27,28,37, as inhibition of its activity negates Pi induced apoptosis 
during terminal differentiation37.  
Although ALP activity is highly upregulated in hypertrophic and terminally differentiated 
chondrocytes during endochondral ossification32, Pi is present in the resting and proliferative zones 
of the growth plate38. However, few studies have investigated whether chondrogenic 
differentiation or early events in the endochondral ossification pathway are regulated by Pi. Kimata 
et al. demonstrated that Pi treatment upregulated cell proliferation through ERK1/2 mediated 
cyclin D1 expression in the ATDC5 cell line and primary chondrocytes28. Wang et al. also showed 
that transient Pi treatment upregulated collagen type II gene expression34. Taken together with the 
previously reported expression profile of PiT-1 and activity of ALP, these studies suggest that Pi 
plays a direct regulatory role in early chondrogenic differentiation and proliferation during 
endochondral ossification.  
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To elucidate the role of phosphate in early chondrogenic events, we used ATDC5 cells in 
2D and 3D cultures. This cell line, established by Atsumi et al. from the mouse teratocarcinoma 
cells AT805, recapitulate the phases of endochondral ossification, from chondrogenic commitment 
to hypertrophic differentiation, with the addition of insulin39–41.  In these cells, chondrogenic 
maturation and matrix mineralization occur on an accelerated timescale if given an exogenous 
source of phosphate10,11. Since ALP activity has also been shown to change as chondrocytes 
differentiate and mature32,42, we used β-glycerophosphate (βGP) as our phosphate source to ensure 
cells control the release of phosphate. Although 10mM βGP is considered a supraphysiologic 
concentration of organic phosphate for in vitro studies43, it was found in this study that the 
maximum Pi concentration in the media using this level of βGP is 4mM, the concentration 
employed in many previous mechanistic studies9,28,34. So that the Ca × Pi never reaches levels that 
lead to dystrophic precipitation of CaPO4, calcium concentration was maintained at 1.3mM
30,44. 
Using this media formulation, we found that the response of chondroprogenitor cells was regulated 
by Pi availability on a per cell basis (Pi abundance). Specifically, moderate Pi abundance 
upregulates markers of chondrogenesis whereas high abundance levels inhibit chondrogenesis and 
stimulate rapid matrix mineralization. We also show that this biphasic response to Pi concentration 
is mediated by ALP activity and cellular uptake of Pi and is dependent on the maturation stage of 
chondrocytes. Finally, delaying the addition of exogenous phosphate to ATDC5 cells in 3D 
cultures upregulates the expression of hypertrophic markers and accelerates terminal 
differentiation without dystrophic mineral formation, demonstrating that this culture system may 
serve as a rapid and physiologic model of endochondral ossification. 
3.2 Methods 
3.2.1 Cell culture 
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ATDC5 cells (Sigma) were maintained in DMEM/F12 (Life Technologies) supplemented 
with 5% FBS (Life Technologies) and 1% Antibiotic-Antimycotic (Life Technologies). 
Chondrogenesis of ATDC5 cells was induced with chondrogenic differentiation medium (ITS+) 
consisting of the growth medium supplemented with 1% ITS+ Premix (Corning) and 50 µg/ml 
ascorbate acid-2-phosphate (Sigma). Co-treatment medium (ITS+/βGP) consists of ITS+ medium 
supplemented with 10 mM β-glycerophosphate (Sigma). Non-chondrogenic mineralizing medium 
(βGP) consists of growth medium supplemented with 10mM βGP. Calcium concentration was 
maintained at 1.3mM. 
3.2.2 Monolayer (2D) culture  
Four days prior to chondrogenic induction, cells were seeded at the density of 6000 
cells/cm2 in multiple well plates. When cells reached 100% confluence (D0), differentiation was 
initiated by replacing the growth medium with differentiation medium. Cultures were fed with 2ml 
medium every other day and maintained for 21 days. 
3.2.3 Pellet (3D) culture  
Four days prior to chondrogenic induction, cells were seeded at the density of 6000 
cells/cm2. When cells reached 100% confluence (D0), they were trypsinized and centrifuged into 
pellets containing 2.5×105 cells in round-bottomed polypropylene 96-well-plate. Cultures were fed 
with 200µl medium every other day. Pellet cultures were maintained for 21 days with 
differentiation medium. In delayed treatment, pellets were switched to ITS+/βGP medium after 7 
or 14 days in ITS+ medium. 
3.2.4 Biochemical analysis 
Cartilage-specific matrix production was measured by the 1,9-dimethylmethylene blue 
(DMMB) assay as previously described 45. Both monolayer cell tissues and pellets were digested 
with 1 mg/ml proteinase K in 0.1M ammonium acetate at 50°C for 16 hours. Digested samples 
50 
 
were mixed with DMMB dye (pH 1.5) at a ratio of 1:20, and the GAG content of the samples were 
determined by comparing the ratio of 525 nm to 595 nm readings to the standard curve derived 
from shark chondroitin sulfate. Measured GAG content of each sample was normalized by its 
DNA content using Hoechst 33258 dye (Sigma) as previously described 46. To measure mineral 
content of each sample, insoluble residues from the proteinase K digestion were collected and 
hydrolyzed by with 10% (w/w) acetic acid for 48 hours at 40°C. Hydrolyzed solution was added 
to Arsenazo III dye (Pointe Scientific) at ratio of 1:15, and the absorbance was read at 650 and 500 
nm. The mineral content was calculated by comparing the ratio of these two absorbance readings 
to a standard curve created from calcium chloride. 
3.2.5 Gene expression  
Total RNA of each sample was extracted using TRI Reagent® RT (Molecular Research 
Center). For pellet culture, five pellets were combined and homogenized in the same reagent using 
the Micro Tube Homogenizer. Equal amounts of extracted RNA were reverse-transcribed into 
cDNA using High-Capacity cDNA Reverse Transcription Kit (Life Technologies). Synthesized 
cDNA was amplified using SYBR® Green PCR Master Mix (Life Technologies) on Applied 
Biosystems® 7500 Fast platform. The mean cycle threshold of the housekeeping genes ( hkCt ) 
Hprt and Ppia47 were used to calculate the fold change in transcript levels compared to day 0 
samples using the Ct  method. Relative expression levels were calculated as 2
Ctx  , in which
Ct E C    , exp hkE Ct Ct    at the time-point of interest, and exp hkC Ct Ct    at day 0. 
The forward and reverse primer sequences are listed in Table 3-1.  
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Table 3-2. The sequences of primers used 
 
3.2.6 Histological analysis 
Monolayer cultures were washed with PBS, and fixed in 70% ethanol at 4℃ for 16 hours. 
Differentiated pellets were washed with PBS, and fixed in 5% buffered formalin at 4℃ for 16 
hours. Fixed pellets were washed with 70% ethanol, embedded in paraffin wax, and then 7 µm 
sections were taken. Proteoglycan accumulation in monolayer tissues and pellets was evaluated by 
staining the sectioned tissue with 3% Alcian blue dye (Poly Scientific), and calcium deposition 
was visualized by staining with 2% Alizarin red S dye (pH 4.3).  
3.2.7 Alkaline Phosphatase Activity Analysis 
Alkaline phosphatase activity was measured by the QuantiChrom™ Alkaline Phosphatase 
Assay Kit (BioAssay Systems). Both monolayer cell tissues and pellets were washed with PBS, 
then lyzed in 0.2% Triton-100 solution for 30 minutes at room temperature. Upon addition of lysis 
buffer, pellet samples were ground with a pestle to break apart the tissue. Alkaline phosphatase 
activity was determined by taking the ratio of the difference between 405 nm readings taken 
immediately after adding the assay buffer (t=0) and after 4 minutes on a plate reader to the 
difference between the 405 nm readings of the calibrator (Tartrazine) and deionized water using 
the equation from the manufacturer’s protocol.  
Gene
Acan Forward CGCCACTTTCATGACCGAGA Reverse CAAATTGCAGAGAGTGTCCGT
Col2a1 Forward ACGAGGCAGACAGTACCTTG Reverse AGTAGTCTCCGCTCTTCCACT
Col10a1 Forward CCAAACGCCCACAGGCATAA Reverse TGCCTTGTTCTCCTCTTACTGG
Hprt Forward CTGGTGAAAAGGACCTCTCGAA Reverse CTGAAGTACTCATTATAGTCAAGGGCAT
Ppia Forward CGCGTCTCCTTCGAGCTGTTTG Reverse TGTAAAGTCACCACCCTGGCACAT
Sox9 Forward CGGAACAGACTCACATCTCTCC Reverse GCTTGCACGTCGGTTTTGG
Runx2 Forward CCACGGCCCTCCCTGAACTCT Reverse ACTGGCGGGGTGTAGGTAAAGGTG
Ctnnb1 Forward CACAGCTCCTTCCCTGAGTG Reverse CTGCCCGTCAATATCAGCTACT
Axin2 Forward AAGCCCCATAGTGCCCAAAG Reverse GGGTCCTGGGTAAATGGGTG
Slc20a1 Forward GGAACGGCTTGATAGATGTGG Reverse GCAGAACCAAACATAGCACTGAC
Slc20a2 Forward CCGTCCAGTGGCTTCACTAT Reverse AGTCACGAACCAGGCAACAA
Osteopontin Forward AGCAAGAAACTCTTCCAAGCAA Reverse GTGAGATTCGTCAGATTCATCCG
Osteocalcin Forward GCCCTGAGTCTGACAAAGGTA Reverse GGTGATGGCCAAGACTAAGG
Primer Sequences (5'→3')Primer Sequences (5'→3')
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3.2.8 Phosphate Concentration Analysis 
Concentration of phosphate in the media was determined using the QuantiChrom™ 
Phosphate Assay Kit (BioAssay Systems). Media from each test condition was harvested and 
diluted 1:20 with water prior to the addition of assay reagent. Phosphate concentration was 
determined by reading optical density at 620 nm, followed by calculation using equations given in 
the manufacturer’s protocol.  
3.2.9 Statistical analysis 
Statistical analysis was performed using GraphPad Prism software. All comparisons over 
multiple time points were analyzed by two-way ANOVA with Tukey’s multiple comparison 
method. Comparisons in experiment at a single time point were analyzed by one-way ANOVA 
followed by Sidak correction. Significant difference is indicated by * P<0.05, ** P<0.01, 
***P<0.001, ****P<0.0001. All error bars indicate the standard error of the mean (s.e.m.). 
3.3 Results  
3.3.1 The influence of βGP supplementation on early chondrogenesis in 2D and 3D cultures  
To better understand the individual and synergistic effects of βGP on early chondrogenesis, 
we monitored the gene expression of early chondrogenic markers, Acan and Col2a1 gene 
expression as well as the amount of cartilaginous matrix produced by ATDC5 cells in both high 
density monolayer (2D) and pellet (3D) cultures. Both culture types were treated with ITS+, βGP, 
or ITS+/βGP for 14 days. Notably, the expression of genes and matrix components were 2-10 
times higher in 3D cultures compared to 2D. Nonetheless, both 2D and 3D cultures exhibited a 
similar trend of chondrogenic gene expression and matrix accumulation when they were treated 
with ITS+ or βGP individually. Chondrogenesis and proliferation (not shown) of chondrogenic 
cells occurs within the first 7 days of culture in ITS+ medium in 2D and 3D. Upregulation of Acan 
and Col2a1 gene expression (Fig 3-1a) and production of sGAG-rich matrix (Fig 3-1b & 1d) in 
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both monolayer and pellet cultures treated with ITS+ confirmed early chondrogenesis. In the 
absence of ITS+, cells cultured in medium supplemented with 10mM βGP did not express 
chondrogenic markers in either culture type (Fig 3-1a, b & d) and induced rapid mineralization of 
the matrix (Fig 3-1c & e). The response to combined ITS+/βGP treatment, however, was dissimilar 
in the two systems. In monolayer culture, cells differentiated with ITS+/βGP showed significantly 
higher mRNA levels of Acan and Col2a1 (Fig 3-1a) as well as a 1.6-fold increase in accumulation 
of an sGAG-rich matrix (Fig 3-1b & 1d) compared the ITS+ alone group. Mineral also formed in 
these cultures, but did not appear to be associated with nodules of chondrogenic cells. Conversely, 
the addition of βGP to ITS+ treated pellet cultures suppressed expression of Acan and Col2a1 
genes and matrix accumulation and stimulated mineralization.  
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Figure 3-1. Differential effects of ITS+/βGP co-treatment on early chondrogenesis of ATDC5 cells in 2D and 
3D cultures. (a) Quantification of mRNA expression (relative to day 0 and the housekeeping genes Hprt and Ppia) 
of early chondrogenic markers (Acan and Col2a1) in monolayer (2D) and pellet (3D) cultures over 14 days of 
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differentiation. Fold change (relative to day 0) in sGAG accumulation (b) and calcium deposition (c) normalized to 
DNA content over 14 days of differentiation in 2D and 3D cultures treated with ITS+ or ITS+/βGP. (d) Alcian blue 
staining of 2D and 3D cultures at day 14 to show accumulation of sGAG-rich matrix. 3D cultures stained also with 
nuclear fast red counterstain to show cell structure. (e) Alizarin Red staining of 2D and 3D cultures at day 14 to show 
mineral content in each sample. Data represented as mean ± s.e.m. Significant difference from the ITS+ group at the 
same time point (n≥8) is indicated by * P<0.05, ** P<0.01, ***P<0.001, ****P<0.0001 by two-way ANOVA with 
Tukey’s multiple comparison method. NS, not significant. 
 
3.3.2 The culture-dependent effect of ITS+/βGP on early chondrogenesis is regulated by ALP 
activity and Pi abundance. 
To determine if the effects of βGP supplementation on ATDC5 cells is controlled by cell-
mediated regulation of Pi availability, we measured the ALP activity of the cells and subsequent 
Pi concentration in the media of both systems during early chondrogenesis (days 1, 3, 5, and 7). 
The ALP activity of cells in monolayer cultures (Fig 3-2a) induced with ITS+ alone or ITS+/βGP 
increased steadily over the first 7 days. In comparison, cells treated with βGP only had a higher 
level of ALP activity, which peaked at day 3 and was maintained until day 5. By day 7, ALP 
activity was similar in all 2D culture conditions. In contrast to 2D cultures, ALP activity was 
highest in cells on day 1 in 3D–ITS+ cultures and then rapidly decreased as differentiation 
proceeded during the first week. When pellets were treated with βGP or co-treated with ITS+/βGP, 
ALP activity was maintained at this high level through day 3 and then decreased to levels similar 
to the 3D–ITS+ control group (Fig 3-2d).  
The basal concentration of Pi in the medium of 2D and 3D ITS+-treated cultures was 1mM 
(the concentration in DMEM/F12). With βGP treatment, Pi concentration in the medium increased 
to 4mM on average in 2D cultures from days 3-7 (Fig 3-2b) regardless of ALP activity. Slightly 
lower Pi levels (~3.6mM on average) were found in 3D cultures treated with βGP or ITS+/βGP 
(Fig 3-2e).  
We further estimated the Pi availability on a per cell basis by normalizing the total Pi 
content in the medium by total DNA content (Fig 3-2c & f), which we are defining as Pi abundance. 
Three levels of Pi abundance were observed and were found to be dependent on culture condition 
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(2D vs. 3D) and ITS+ and/or βGP supplementation: low abundance (Pi/DNA < 10 ng/µg) was 
found in 2D–ITS+ cultures; moderate abundance (Pi/DNA=25.3 – 32.3 ng/µg) was found in 2D–
ITS+/βGP and 3D–ITS+ cultures; and high abundance (Pi/DNA > 60 ng/µg) was detected in 
culture conditions with the highest-level ALP activity—2D–βGP, 3D–ITS+/βGP, and 3D–βGP. 
As was shown in Fig. 1, groups exposed to moderate Pi abundance levels had enhanced expression 
of Acan and Col2a1 as well as increased sGAG accumulation (Fig 3-1b & 1d) whereas high Pi 
abundance suppressed these markers in 3D cultures. Thus, high Pi abundance correlates with 
inhibition of early chondrogenesis while moderate Pi abundance correlates with enhanced 
chondrogenic differentiation. 
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Figure 3-2. The culture-dependent effect of ITS+/βGP on early chondrogenesis is regulated by ALP activity 
and Pi abundance. (a & d) Normalized ALP activity, (b & e) Pi concentration (mM) present in the medium, and (c 
& f) Pi availability on a per cell basis during the first seven days of differentiation in 2D and 3D cultures treated with 
ITS+, ITS+/βGP, or βGP (n=3). Data represented as mean ± s.e.m. Significant difference from the ITS+ group at the 
same time point is indicated by * P<0.05, ** P<0.01, ***P<0.001, ****P<0.0001 by two-way ANOVA corrected 
with Tukey’s multiple comparison method. NS, not significant. ¥ indicates significance difference between ITS+/ βGP 
and βGP conditions at the same time point (P<0.0001). 
To explore the possible pathways that could be involved in mediating the response to 
available levels of Pi to the cells, we examined the gene expression of mediators of chondrogenesis 
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(Sox9), chondrocyte hypertrophy (Runx2), and a known inhibitor of chondrogenesis, β-catenin 
(Ctnnb1) as well as their gene targets (Col2a1, Col10a1, and Axin2, respectively) before, during, 
and after the change in Pi abundance at day 1, day 3, and day 7. Although Pi abundance increased 
in response to additional βGP supplementation starting at day 3, there were not significant 
discrepancies in gene expression between groups with different Pi levels until day 7. The increase 
in Pi abundance from low to moderate (comparing 2D ITS+ to 2D ITS+/βGP) correlated with 
higher mRNA levels of Sox9 and its gene target Col2a1, as well as Col10a1. However, no 
significant difference in the expression of Runx2, Ctnnb1, or Axin2 was observed (Fig 3-3a). The 
shift from moderate to high Pi abundance (comparison of 3D–ITS+ to 3D–ITS+/βGP) resulted in 
elevated Col10a1 gene expression with no associated change in the expression levels of Runx2. 
High Pi abundance also reduced the level of Col2a1 gene expression and increased the gene 
expression of Ctnnb1 and its target Axin2 (Fig 3-3b).  
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Figure 3-3. Gene expression reveals possible pathways involved in the biphasic regulation of Pi.  Quantification 
of mRNA expression (relative to day 0 and Hprt and Ppia) of genes and downstream effectors associated with early 
chondrogenesis and hypertrophy in 2D (a) and 3D (b) cultures treated with ITS+ and ITS+/βGP during the first seven 
days of differentiation. Data represented as mean ± s.e.m. Significant difference from the ITS+ group at the same time 
point is indicated by * P<0.05, ** P<0.01, ***P<0.001, ****P<0.0001 by two-way ANOVA with Tukey’s multiple 
comparisons. NS, not significant. n≥3. 
 
3.3.3 Inhibition of ALP Activity restores early chondrogenesis in 3D  
The next step was to examine if the activity of ALP and Pi uptake by ATDC5 cells played 
a role in the βGP-induced inhibition of early chondrogenesis in 3D cultures. ALP activity and Pi 
uptake were individually inhibited using levamisole and PFA, respectively. In 3D–ITS+/βGP 
cultures, levamisole treatment reduced the Pi abundance to Pi/DNA=48.4 ng/µg after day 3 (Fig 
3-4a). This is a level slightly higher than the moderate range, but the difference was not significant. 
ALP inhibition in the ITS+/βGP group enhanced markers of early chondrogenesis compared to 
3D–ITS+ cultures (moderate Pi abundance). There was a slight increase in Col2a1 gene expression 
over ITS+ controls (Fig. 3-1b; not significant) and significantly higher sGAG expression (Fig 3-
4c & d).  Furthermore, levamisole treatment reduced expression of the phosphoprotein osteopontin 
(OPN), a marker sensitive to phosphate treatment48. Without the addition of βGP, levamisole 
treatment had no effect on chondrogenesis (data not shown). Pi abundance was reduced with 
treatment of PFA, but remained in the high range (Pi/DNA>64.3 ng/µg; Fig 3-4a). Accordingly, 
PFA treated pellets were noticeably smaller than other conditions. In these pellets, Col2a1 
expression and matrix deposition were inhibited (Fig 3-4b & c). Taken together with the response 
of the cells exposed to moderate Pi abundance in 2D cultures, the response of ATDC5 cells to both 
inhibitors in 3D indicates that phosphate uptake is required for early chondrogenesis and that a 
moderate level of phosphate will enhance matrix production of chondrocytes.  
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Figure 3-4. Inhibition of ALP Activity or Pi uptake restored early chondrogenesis in 3D. (a) Pi availability on a 
per cell basis in 3D culture treated with ITS+, ITS+/βGP, ITS+/βGP/levamisole, or ITS+/βGP/PFA during the first 
seven days of differentiation. (b) Quantification of mRNA expression (relative to day 0 and Hprt and Ppia) of the 
chondrogenic marker Col2a1 and phosphate uptake marker OPN at day 7 of differentiation. (c) Alcian blue and 
alizarin red staining of 3D cultures treated with ITS+, ITS+/βGP, ITS+/βGP/levamisole, or ITS+/ βGP/PFA at day 14 
of differentiation. Pellets stained with Alcian blue were also stained with nuclear fast red counterstain to show cell 
structure. (d) Fold change in sGAG accumulation normalized to DNA content (relative to day 0) over 21 days of 
differentiation in 3D cultures treated with ITS+ or ITS+/βGP/levamisole. Data represented as mean ± s.e.m. 
Significant difference from the ITS+ group at the same time point is indicated by * P<0.05, ** P<0.01, ***P<0.001, 
****P<0.0001 by one-way or two-way ANOVA with Tukey’s multiple comparisons. NS, not significant. n≥3. 
 
3.3.4 Delayed βGP supplementation expedites late chondrogenesis in 3D cultures 
To determine if the biphasic response to βGP continues after early chondrogenesis, βGP 
treatment was delayed for 7 or 14 days in pellet cultures. While Pi abundance was significantly 
increased in both delayed groups once βGP was added, the level remains in the moderate range 
(Pi/DNA<42 ng/µg; Fig 3-5a). The expression of Acan or Col2a1 genes on days 14 and 21 of 
culture was comparable to or slightly higher than the ITS+ group (not significant; Fig 3-5c). 
Accordingly, the βGP-induced inhibition of sGAG production was not observed as demonstrated 
61 
 
by histological staining (Fig 3-5b) and quantification of sGAG production (Fig 3-5d).  Instead, 
sGAG accumulation was increased in the 7-day delayed group 1 week after the addition of βGP. 
By day 21 of culture, sGAG levels in both delayed groups were equivalent to the ITS+ group.  
Col10a1 gene expression was upregulated by day 21 in the 7-day delayed group over 
cultures treated with ITS+ alone or ITS+/βGP from day 0 (Fig 3-5c).  Calcium accumulation was 
the same 7 days after βGP addition in both delayed groups, which was 13.5% of the amount 
accumulated when βGP was added from day 0 (Fig 3-5e). Notably, calcium deposition in the 
delayed group did not occur linearly as observed in cultures with βGP from day 0. Thus, moderate 
Pi abundance induces hypertrophy and mineralization in ATDC5 cells without altering their 
chondrogenic response. 
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Figure 3-5. Delayed βGP supplement expedites late chondrogenesis. (a) Pi availability on a per cell basis in 3D 
culture treated with ITS+, and ITS+/βGP supplemented from day 0, day 7, day 14 during 21 days of differentiation. 
(b) Alcian blue and alizarin red staining of delayed 3D cultures at day 21. Fold changes in mRNA expression (relative 
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to day 0 and the housekeeping genes Hprt and Ppia) of early and late chondrogenic markers (Acan, Col2a1, and 
Col10a1) (c), normalized sGAG accumulation (d), and normalized calcium deposition (e) in delayed 3D cultures over 
21 days of differentiation. (f) Comparison of fold changes in normalized calcium deposition between 7-day delayed 
and no delay 2D and 3D cultures after βGP supplementation. Data represented as mean ± s.e.m. Significant difference 
between ITS+ and other conditions at the same time point is indicated by * P<0.05, ** P<0.01, ***P<0.001, 
****P<0.0001 by two-way ANOVA with Tukey’s multiple comparison method. NS, not significant. n≥4. 
3.4 Discussion & Conclusion 
Here we demonstrate that the availability of Pi on a per cell basis and the maturation point 
of chondroprogenitor cells both determine their response to phosphate during endochondral 
ossification. Using the measure of Pi abundance, we show that there is a biphasic response to 
phosphate during early chondrogenesis – moderate levels enhance chondrogenesis and matrix 
production whereas, if the differentiating chondrocytes are exposed to high levels during early 
endochondral ossification, chondrogenesis is inhibited and rapid calcification ensues. The 
observed discrepancy in Pi abundance between 2D and 3D systems also highlights the culture-
dependent ALP activity in response to βGP. It was possible to reduce Pi abundance to moderate 
levels by partially inhibiting ALP activity, which reversed βGP-induced suppression of 
chondrogenesis. Similar to 2D cultures, moderate Pi abundance increased expression of 
chondrogenic markers and deposition of sGAG-rich matrix in 3D cultures. After early 
chondrogenesis (7-10 days), the response to βGP delivery by these cells is no longer biphasic and 
hypertrophy makers are upregulated. Thus, the cell response to Pi is maturation-dependent.  
We show that it is important to evaluate the effect of Pi on chondrogenesis by examining 
its availability on a per cell level. Emerging evidence has shown that Pi can function as a signaling 
molecule to regulate cellular functions and differentiation of MSCs14, osteoblasts15, and 
chondrocytes9,49. In both osteoblasts and chondrocytes, the signaling function of Pi was shown to 
be mediated by phosphate influx through sodium-dependent phosphate transporters14,34.  In culture, 
the volume of medium and number of cells present, in addition to the concentration of Pi, would 
affect the Pi influx among individual cells. Taking these factors into consideration, the availability 
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of Pi on a per cell level is significantly different in two scenarios reported here. First, 2D and 3D 
culture have different ratios of medium volume to the number of cells in individual wells, resulting 
in culture-dependent discrepancy in Pi abundance. Second, significant proliferation occurs during 
the chondrogenic differentiation in both systems, changing the cell number in the culture. Thus, Pi 
abundance decreases as differentiation proceeds, which, as we have shown, alters cellular response. 
Thus, these factors should be accounted for in studies of the effects of exogenous phosphate on 
cell function.  
The literature indicates that Pi both negatively and positively regulates early 
chondrogenesis28,34,50–56. Our results strongly suggest a biphasic model that may explain these 
discrepancies. For instance, recent studies that have shown that the Wnt/β-catenin pathway 
prevents MSCs chondrogenesis50,51, possibly promoted by A2b adenosine receptor activity that is 
mediated by cellular phosphate uptake through PiT-152 53–55. In accordance with these studies, we 
observed increased gene expression of Ctnnb1 (β-catenin) and its target gene, Axin2, as well as 
decreased Sox9 activity, extrapolated from decreased expression of Col2a1, in the high Pi culture, 
which suggests that high Pi abundance inhibits early chondrogenesis through upregulation of β-
catenin activity. The measured increase in Sox9 expression and activity in response to moderate 
Pi conditions in our studies agrees with the results of Wang et al., which reported upregulation of 
PiT-1 and Col2a1 gene and protein expression in response to short-term Pi treatment (24hr) in 
differentiating CFK2 cells34. Additionally, Kimata et al. demonstrated that 4mM Pi enhanced 
proliferation in early stages of chondrogenic differentiation of ATDC5 cells and primary 
chondroprogenitors through phosphorylation of ERK1/228, a pathway also involved in the 
upregulation of aggrecan expression56. To our knowledge, most literature on the signaling function 
of phosphate reports Pi level in the form of medium concentration. Therefore, it is difficult to 
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correlate previous results with the biphasic effect observed here without calculating the numbers 
of cells used in those studies. Future studies that monitor Pi abundance may resolve the biphasic 
response observed here and in the literature. 
Delaying βGP supplementation in pellet culture until after the progression of early 
chondrogenesis prevented exposing the cells to high Pi abundance during this stage, as cells rapidly 
reduced their ALP activity after differentiation was initiated. This model may better reflect in vivo 
conditions, as ALP activity is detected in bone marrow chondroprogenitor cells but not in resting 
or proliferative chondrocytes in growth plate32. The moderate increase in the Pi abundance in the 
delayed model also led to a mineral deposition profile that resembles the physiological 
mineralization of cartilage matrix57,58, unlike the linear mineral formation observed in non-delayed 
group. This may be due to the presence of matrix deposited during early chondrogenesis. For 
example, aggrecan, a high molecular weight proteoglycan, has been reported to inhibit the growth 
mineral crystals59–61. Degradation and reorganization of collagen are also important for correct 
mineral formation in bone62,63. Therefore, this model may be used to further evaluate the role of 
matrix accrual and modification on the response of chondroprogenitor cells to phosphate and 
cartilage mineralization during endochondral ossification as well as diseases, such as osteoarthritis. 
Some limitations of this study need to be considered. Our analyses are based on 
extracellular Pi concentration in the medium, which may not directly reflect Pi uptake by the cells. 
It would be interesting to measure the phosphate influx into the cells to further clarify the role of 
Pi in regulating early chondrogenesis. Moreover, the ATDC5 cell line used in this study is derived 
from embryonic teratocarcinoma. While the response of this cell line has been verified in primary 
cells in many studies28,64,65, additional experiments designed to investigate the role of Pi in primary 
chondrocytes and stem cells will help validate our findings. Furthermore, we have neglected the 
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contribution of other regulatory proteins, such as glycoprotein-1 (PC-1) and ankylosis protein 
(ANK) and phosphatases such as phosphatase orphan 1 (PHOSPHO1), that have been shown to 
mediate the balance of PPi/Pi in mineralizing cultures. Future studies will determine the role of 
these factors in mediating the biphasic response of ATDC5 cells to Pi. 
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Chapter 4 Self-regulatory RUNX2 Silencing Gene Circuits Improve MSC-based Cartilage 
Regeneration 
4.1 Introduction 
Mesenchymal stem cell (MSC)-based cartilage tissue engineering has great potential to 
repair cartilage damage. The chondrogenic potential of these highly proliferative stem cells has 
been well proven1,2,3. Compared to isolating autologous chondrocytes from patients’ already 
injured cartilage, harvesting MSCs, usually from the iliac crests, is less invasive and less prone to 
donor site morbidity. However, chondrocytes differentiated from MSCs (MdChs) only maintain a 
transient articular phenotype before further differentiating to the hypertrophic phenotype, 
recapitulating aspects of the maturation program of chondrocytes during endochondral 
ossification4,5. At the hypertrophic stage, chondrocytes stop producing and start degrading the 
structural matrix macromolecules aggrecan and type II collagen, compromising the mechanical 
integrity of the overall tissue. The inferior mechanical properties of tissues derived from MdChs 
pose major concerns for articular cartilage repair6. 
Many molecular and biophysical cues stimulate chondrocyte hypertrophy, such as IHH7, 
TGF-β8, Wnt/β-catenin9, Smad10, and calcium11. Each of these pathways promote chondrocyte 
maturation via Runx2 activity 9,12,13. Using a doxycycline-inducible lentiviral system, we 
demonstrated that RNAi of Runx2 in differentiating chondrocytes can effectively suppress markers 
of hypertrophy and enhance matrix accumulation by targeting RUNX2-activated degradation from 
MMP13 in chapter 2. However, we also found that loss of RUNX2 function in undifferentiated 
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progenitor cells blocks in vitro chondrogenesis. To target the timing of RUNX2 suppression and 
to maintain suppression of basal RUNX2 levels in long-term applications (e.g. after the 
implantation of engineered tissues into a focal defect), tissue-specific promoters can be used to 
direct RUNX2 silencing to exclusively target maturing chondrocytes after chondrogenesis 
occurred in MdChs.  Therefore, maturation-associated matrix degradation due to RUNX2 activity 
can be inhibited while undifferentiated stem cells can continue to develop into matrix-producing 
chondrocytes, maximizing the overall accumulation of articular cartilage-specific structural 
macromolecules.  
Tissue-specific promoters only represent a small portion of mammalian promoters14; 
however, they are essential to the function of a physiological system consisting of different 
types of cells. For example, more than 400 distinct types of cells arise from a single fertilized egg 
during human development15. Although they all carry the identical genetic information, each cell 
type expresses a signature profile of activated genes under the control of tissue-specific 
promoters16, contributing to a certain phenotype. In mammalian cells, gene promoters can be 
separated into two classes: “broad” and “sharp”17, and tissue-specific ones often belong to the 
“sharp” category because of their well-defined, narrow transcription start sites (usually less than a 
few nucleotides)18,19. Such a focused pattern of transcription start sites likely require 
transcription to be initiated by particular transcription factors, contributing to the tissue-specific 
gene expression. Applications of tissue-specific promoters in biomedical research typically follow 
the discovery of a cell type-specific marker, such as osteoblast/osteocalcin20, pancreatic β 
cell/insulin 21, hepatocytes/Albumin-α-Fetoprotein22, cardiomyocytes/myosin heavy chain23, 
mammary epithelial cells/milk whey acidic protein24, articular chondrocytes/aggrecan25, etc. 
Frequently, the promoters of these marker genes are used to create conditional knock-out mouse 
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models to avoid premature deaths from a global disruption of essential genes26,27,28. With an 
increasing number of tissue-specific promoters become available, hundreds of different genes have 
been knocked out in various cell types. (e.gs., chondrocytes 29, pancreatic β cells30, suprabasal 
urothelial cells31, hepatocytes32, cardiomyocytes33, and mammary epithelial cells34).      
Tissue-specific promoters can also help target the early and late chondrogenic phenotypes. 
When mesenchymal progenitors first differentiate into chondrocytes, they express a high level of 
Col2a1 gene35. Using the Col2a1 promoter, chondrocyte-specific knockout of Vegf 36, Fosl2 37, 
Trsp 38, Pten 39, Nf1 40, Smo 41, and Ext142 mice have been created to study the roles of these protein 
in chondrogenesis. Among chondrocytes that are not programmed to become articular 
chondrocytes, they soon transition to the pre-hypertrophic and hypertrophic phenotype, 
accompanied by the upregulated gene expression of type X collagen43. Because of the its unique 
specificity to chondrocyte hypertrophy, the promoter of Col10a1 have been extensively 
characterized and used to generate transgenic mice models 44,45. Recently, Gebhard et al. showed 
that the expression of Col10a1 in murine chondrocytes is controlled by its promoter up to 4.6 kb 
upstream of the transcription start site46. Zheng et al. further identified a 150-bp cis-enhancer 
within the distal region ( -4.4kb to -3.8 kb) that directly contributes to the specific expression of 
Col10a1 in hypertrophic chondrocytes via Runx2 binding47. Therefore, the Col10a1 promoter can 
be used to initiate in vitro transcription confined to pre-hypertrophic or hypertrophic chondrocytes. 
We hypothesize that a Col10a1-like promoter can initiate RUNX2 silencing exclusively in 
maturing chondrocytes without interfering with early chondrogenesis of MSCs. Since larger size 
vectors often reduce the efficiency of viral packaging, truncated versions (<1kb) of the endogenous 
tissue-specific promoters are often created to drive transgene expression or RNAi in certain cell 
types. To minimize the size of the RUNX2 silencing gene circuit, we designed a synthetic cis 
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promoter which consists of a single or multiple copies of the 150-bp cis-enhancers immediately 
upstream of the basal promoter of Col10a1 to recapitulate the hypertrophy-specific activity of the 
endogenous Col10a1 promoter. Using these cis promoters to drive miRNA-based shRunx2 
(referred as cis-shRunx2 gene circuits), we show that these gene circuits can enhance the 
accumulation of matrix by MSC-derived chondrocytes via tunable negative-feedback regulation 
of intracellular RUNX2 activity. 
4.2 Methods 
4.2.1 Synthesis of cis Promoter  
Single copies of Col10a1 basal promoter (-220 to 110 bp) and cis-enhancer (-4296 to -4147 
bp) were synthesized by IDT technology. Two PCR amplification reactions of cis-enhancer were 
performed using primers 5’-AAAAATTCAAAATTTTATCGATCACGAGACTAGCCTC-
CTGTTTCACG and 5’-AACAGGAGGCGGATCTAACAGATTGTAGAATCAGAGTA or 
using primers 5’-CAATCTGTTAGATCCGCCTCCTGTTTCACG and 5’-AACAGGAGGCGG-
ATCTAACAGATTGTAGAATCAGAGTA. Col10a1 basal promoter was PCR amplified using 
primers 5’- ATTCTACAATCTGTTGAATTCTCATGCAC and 5’-CGGGCCCGCGGTACC 
GTCGACTGCAGAATT. These PCR products from three amplification reactions were assembled 
into pLenti-CMVtight-eGFP-Puro that was digested with BstBI and PspXI using Gibson 
Assembly Kit. Successfully cloned plasmid containing 1cis, 2cis, and 3cis promoters were 
confirmed by Sanger sequencing: 1cis-eGFP-Puro, 2cis-eGFP-Puro, and 3cis-eGFP-Puro.  
4.2.2 Synthesis of cis-shRunx2 Gene Circuit and Viral Production 
1cis-Luc-shRunx2 was made by first digesting Tet-on-Luc-shRunx2 with NheI and AgeI to 
remove the Tet-on (TRE2) promoter. 1cis promoter was PCR amplified from 1cis-eGFP-Puro 
using primers 5’-GTTCTAGGCTAGCTTAAAGGATTTTATCGATCACGAGACT and 5’-
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GGTGGCGACCGGTAGGCTGGTACCGAGCTCGAATTCTCCA, and then digested with NheI 
and AgeI. Digested 1cis promoter was ligated to Tet-on-Luc-shRunx2 vector. To remove luciferase 
from 1cis-Luc-shRunx2, mir30-shRunx2 was PCR amplified using primers 5’-
GATCCAGCCTACCGGTAAGCCTTGTTAAGTGCTCGC and 5’-CTAAAGTAGCCCCTT-
GAATTCCGAGGCAGTAGGCA. The PCR product was digested with EcoRI and AgeI, and then 
ligated to 1cis-Luc-shRunx2 that was also digested with EcoRI and AgeI. Similarly, 2cis-Luc-
shRunx2, 2cis-shRunx2, 3cis-Luc-shRunx2, 3cis-shRunx2 and their corresponding scramble 
vectors were synthesized as described above. Correct cloning was confirmed by Sanger sequencing 
at UM Sequencing core, and lentiviral supernatant of the correct plasmid vectors was produced at 
UM Vector Core. 
4.2.3 Chondrogenic Cell Cultures 
ATDC5 cells (Sigma) were maintained in DMEM/F12 (Life Technologies) supplemented 
with 5% FBS (Life Technologies) and 1% Antibiotic-Antimycotic (Life Technologies). 
Chondrogenesis of ATDC5 cells was induced with chondrogenic differentiation medium 
consisting of the growth medium supplemented with 1% ITS+ Premix (Corning) and 50 µg/ml 
ascorbate acid-2-phosphate (Sigma).  
Four days prior to chondrogenic induction of ATDC5 in monolayer (2D) culture, cells were 
seeded at a density of 10,000 cells/cm2 in multiple well plates. When cells reached 100% 
confluence (D0), chondrogenesis was initiated by replacing the growth medium with 
differentiation medium. Cultures were fed with fresh medium every other day and maintained up 
to 28 days. 
Four days prior to chondrogenic induction in pellet (3D) culture, cells were seeded at a 
density of 10,000 cells/cm2. When cells reached 100% confluence (D0), they were trypsinized and 
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centrifuged into pellets containing 2.5×105 cells in round-bottomed polypropylene 96-well-plate. 
Chondrogenesis was initiated by replacing the growth medium with differentiation medium and 
maintained for 35 days.  
C57BL/6 Mouse Mesenchymal Stem Cells (Cyagen) were maintained according to 
manufacturer’s instruction. Chondrogenesis of mMSCs was induced with chondrogenic 
differentiation medium consisting of DMEM(high-glucose) supplemented with 0.1 μM 
dexamethasone, 50 μg/mL ascorbate 2-phosphate, 40 μg/mL L-proline, 100 μg/mL sodium 
pyruvate, 1% ITS+, 50 ng/mL BMP-2, and 10 ng/mL TGF-β3. When cells reached 85% 
confluence (D0), they were trypsinized and centrifuged into pellets containing 2.0×105 cells in 
round-bottomed polypropylene 96-well-plate. Chondrogenesis was initiated by replacing the 
growth medium with differentiation medium and maintained for 56 days.  
4.2.4 Luciferase Assay 
Luciferase activity of ATDC5 cultures in multiple wells was measured daily. D-luciferin 
stock was added to the culture medium at a final concentration of 150 µg/mL and gently mixed. 
Luciferin-added cultures were incubated at 37°C for 30 minutes before measured using 
SYNERGY H1 microplate reader (BioTek). Each plate was measured three times to minimize 
reading machine errors. Measured cultures were fed with fresh differentiation medium afterward. 
4.2.5 Biochemical Analysis 
Cartilage-specific matrix production was measured by the 1,9-dimethylmethylene blue 
(DMMB) assay as previously described 48. Both monolayer cell tissues and pellets were digested 
with 1 mg/ml proteinase K in 0.1M ammonium acetate at 50°C for 16 hours. Digested samples 
were mixed with DMMB dye (pH 1.5) at a ratio of 1:20, and the sGAG content of the samples 
were determined by comparing the ratio of 525 nm to 595 nm readings to the standard curve 
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derived from shark chondroitin sulfate. Measured sGAG content of each sample was normalized 
by its DNA content using Hoechst 33258 dye (Sigma) as previously described 49.  
4.2.6 Gene expression Analysis  
Total RNA of each sample was extracted using TRI Reagent® RT (Molecular Research 
Center). For pellet culture, five pellets were combined and homogenized in the same reagent using 
the Micro Tube Homogenizer. Equal amounts of extracted RNA were reverse-transcribed into 
cDNA using High-Capacity cDNA Reverse Transcription Kit (Life Technologies). Synthesized 
cDNA was amplified using Fast SYBR® Green Master Mix (Life Technologies) on Applied 
Biosystems® 7500 Fast platform. The mean cycle threshold of the housekeeping genes ( hkCt ) 
Hprt and Ppia50 were used to calculate the fold change in transcript levels compared to day 0 
samples using the Ct  method. Relative expression levels were calculated as 2
Ctx  , in which
Ct E C    , exp hkE Ct Ct    at the time-point of interest, and exp hkC Ct Ct    at day 0. 
The forward and reverse primer sequences are listed in Table 4-1.  
Table 4-1. The sequences of primers used 
 
4.2.7 Histological Analysis 
Differentiated pellets were washed with PBS and fixed in 5% buffered formalin at 4℃ for 
16 hours. Fixed pellets were washed with 70% ethanol, embedded in paraffin wax, and then 7 µm 
sections were taken. Proteoglycan accumulation in monolayer tissues and pellets was evaluated by 
staining the sectioned tissue with 3% Alcian blue dye (Poly Scientific). 
Gene
Acan Forward CGCCACTTTCATGACCGAGA Reverse CAAATTGCAGAGAGTGTCCGT
Col2a1 Forward ACGAGGCAGACAGTACCTTG Reverse AGTAGTCTCCGCTCTTCCACT
Col10a1 Forward CCAAACGCCCACAGGCATAA Reverse TGCCTTGTTCTCCTCTTACTGG
Hprt Forward CTGGTGAAAAGGACCTCTCGAA Reverse CTGAAGTACTCATTATAGTCAAGGGCAT
Ppia Forward CGCGTCTCCTTCGAGCTGTTTG Reverse TGTAAAGTCACCACCCTGGCACAT
Mmp13 Forward GGAGCCCTGATGTTTCCCAT Reverse GTCTTCATCGCCTGGACCATA
Primer Sequences (5'→3') Primer Sequences (5'→3')
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4.2.8 Immunohistochemical Analysis 
Samples were prepared for immunohistochemical (IHC) staining by fixation in 5% 
formalin. Samples were then embedded in paraffin wax and cut into 7 𝜇m sections. Slides were 
deparaffinized in xylene and rehydrated through decreasing concentrations of ethanol (100%, 95%, 
70%). Antigen retrieval was performed BD Retrievagen A Solution System for 20 minutes at 85 °C 
Blocking of slides was done in 1% BSA and 10% goat serum in PBS for 2 hours at room 
temperature. After blocking, slides were incubated overnight at 4 °C in the following antibodies: 
RUNX2 (Abcam, 23981) and COL10A1 (ABclonal, A6889) are used for overnight primary 
incubation at 4 °C. HRP-conjugated secondary antibody goat anti-rabbit (Abcam, ab97080). Slides 
were developed using DAB Substrate Kit (Abcam, 64238) with hematoxylin counterstaining 
before imaging. 
4.2.9 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software. All comparisons over 
multiple time points were analyzed by two-way ANOVA with Tukey’s multiple comparison 
method. Comparisons in experiment with a single time point were analyzed by one-way ANOVA 
followed by Sidak correction. Significant difference is indicated by * P<0.05, ** P<0.01, 
***P<0.001, ****P<0.0001. All error bars indicate the standard error of the mean (s.e.m.).      
4.3 Results 
4.3.1 Synthetic Col10a1-like Promoters 
We hypothesized that a synthetic promoter consisting of the core promoter sequence of 
Col10a1 and RUNX2 binding sites can recapitulate a specificity to hypertrophic chondrocytes. To 
test this hypothesis, we incorporated a truncated Col10a1 basal promoter downstream of the 150bp 
cis-enhancer to drive the expression of luciferase and eGFP (Figure 4-1). Polyclonal ATDC5 
populations that stably express the luciferase reporter construct were chondrogenically induced 
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and cultured for 21 days in monolayer. Luciferase activity in these differentiating cells was initially 
expressed at a minimal level until day 6, then rapidly upregulated to, and maintained at an elevated 
level after day 10 (Figure 4-2b). Such an activity profile of the 1cis promoter resembles the gene 
expression of Col10a1 (Figure 4-2a).  
 
Figure 4-1. Reporter constructs of 1cis promoter. (a) Diagram of 1cis-Luc. 1cis-Luc encodes the firefly luciferase 
under the control of the synthetic 1cis promoter and a constitutive cassette (puromycin N-acetyltransferase, not 
shown). (b) Diagram of 1cis-eGFP. 1cis-eGFP encodes the enhanced green fluorescent protein under the control of 
the synthetic 1cis promoter and a constitutive cassette (puromycin N-acetyltransferase, not shown). 
To confirm that the 1cis promoter is exclusively activated in cells undergoing 
chondrogenesis, we transduced the cells with the eGFP reporter construct and induced 
chondrogenesis in these cells. By day 7, eGFP fluorescence was only seen in cartilaginous nodules. 
Little eGFP fluorescence was observed in cells that were not chondrogenically induced nor ones 
that had not yet formed cartilaginous nodules (Figure 4-2c). At day 14, we harvested these cells 
for Western blot analysis, which showed that eGFP protein was solely expressed in cells that were 
exposed to chondrogenic stimuli (Figure 4-2d). Taken together, these data illustrate that 1cis 
promoter has a similar phenotype-specificity to endogenous Col10a1 promoter, and its 
transcriptional activity is limited to differentiated ATDC5 cells and upregulated as these cells 
transition to the hypertrophic phenotype. 
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Figure 4-2. Synthetic 1cis promoter resembles endogenous Col10a1 promoter.  (a). Quantification of mRNA 
expression (relative to day 0 and the housekeeping genes Hprt and Ppia) of Col10a1 in non-transduced ATDC5 
monolayer cultures over 21 days of chondrogenic differentiation (two independent experiments, n≥5). (b) Total 
luciferase activity from ATDC5 cultures expressing 1cis-Luc over 21 days of differentiation (two independent 
experiments, n=6).  (c) Bright field and fluorescent imaging of ATDC5 cells transduced with 1cis-eGFP before and 
after 7-day chondrogenic differentiation. (d) eGFP and β-actin (internal control) levels in non-transduced ATDC5 and 
ones transduced with 1cis-eGFP were determined after 14-day chondrogenic differentiation were determined by 
Western blot.   
4.3.2 Activity of RUNX2 Suppressing Gene Circuits  
To determine whether the 1cis promoter could be used to provide self-regulated RNAi of 
RUNX2 in pre-hypertrophic ATDC5 cells, we created a lentiviral vector that co-expresses the 
luciferase cDNA and shRunx2 sequence under the control of the engineered promoter and 
established polyclonal ATDC5 cell populations stably expressing such a vector (Figure 4-3a). As 
chondrogenesis occurred, the luciferase activity, as a surrogate measurement of the promoter 
activation, was expressed at a minimal level in cells expressing 1cis-shRunx2 during the first 6 
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days, similar to that in cells transduced with 1cis-scramble vector. From day 7, 1cis-shRunx2 
cultures exhibited a significantly lower level of luciferase activity than the scramble controls 
(Figure 4-4a). While the total activity from both groups fluctuated throughout further 
differentiation, a relative decrease of 18.1±5.1% activity was reached and stabilized under the 
control of the 1cis-shRunx2 vector, indicating a lower level of RUNX2 activity in cells expressing 
this gene circuit (Figure 4-4b). 
 
Figure 4-3. Design of cis-shRunx2 gene circuits and their corresponding scramble vectors. (a) Diagrams of 1cis-
Luc-shRunx2 and 1cis-Luc-scramble. 1cis-Luc-shRunx2/scramble encode the firefly luciferase immediately upstream 
of the miRNA-based shRunx2 or scramble sequences under the control of 1cis promoter and a constitutive cassette 
(puromycin N-acetyltransferase, not shown). Diagrams of (b) 2cis- and (c) 3cis-Luc-shRunx2 gene circuits and their 
scramble vectors.  
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Figure 4-4. Activity of cis-shRunx2 gene circuits in monolayer ATDC5 model. Total luciferase activity of cultures 
expressing (a) 1cis-Luc-shRunx2/scramble, (c) 2cis-Luc-shRunx2/scramble, and (e) 3cis-Luc-shRunx2/scramble 
during 21-day chondrogenic differentiation. Relative activity of (b) 1cis-, (d) 2cis-, and (f) 3cis-Luc-shRunx2 were 
calculated by normalizing to activity of corresponding scramble controls at each time point. Data represented as mean 
± s.e.m. Significant difference between groups at each time point (n=6 from two independent transduction experiments) 
is calculated by two-way ANOVA with Tukey’s multiple comparison method.  
We similarly synthesized 2cis-shRunx2 and 3cis-shRunx2 gene circuits and their 
corresponding scramble control vectors (Figure 4-3b&c). During the first five days of 
chondrogenic differentiation, gene circuits containing the 2cis promoter exhibited the same level 
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of minimal activity as 1cis. However, starting from day 6, gene circuit activity increased 56.8% 
over 1cis circuits (Figure 4-4c). The stronger 2cis promoter drove the total gene circuit activity in 
2cis-shRunx2 cultures to equilibrate at a level that was 30.4±4.2% lower than the scramble controls 
(Figure 4-4d). The addition of a third cis-enhancer did not further increase the total gene circuit 
activity (Figure 4-4e). Nonetheless, cells expressing 3cis-shRunx2 exhibited a more prominent 
reduction (77.5±2.6%) in gene circuit activity when compared to the scramble controls throughout 
chondrogenic differentiation (Figure 4-4f). Collectively, this data demonstrates the ability of these 
gene circuits to negatively regulate the expression of RUNX2 during chondrogenic differentiation 
as well as the tunable silencing efficacy via adjusting the number of cis-enhancers incorporated 
into the Col10a1-like promoters.  
4.3.3 Effects of RUNX2 Suppressing Gene Circuits on Chondrogenesis 
 To further study how the activity of gene circuits affects chondrogenic differentiation of 
ATDC5 cells, we examined the gene expression of early and late chondrogenic markers (Acan, 
Col10a1, and Mmp13) during and after the peak activity of each circuit. Although all three versions 
(1cis, 2cis, and 3cis) of the RUNX2 silencing circuit lead to less activity of their Col10a1-like 
promoters at both day 14 and 21, significant downregulation of Col10a1 gene expression (34.4% 
decrease compared to the scrambled controls) was detected only in the 3cis-shRunx2 cultures 
(Figure 4-5b). Similar results were obtained for Mmp13 (Figure 4-5c). Interestingly, 
differentiating cells expressing both 2cis- and 3cis-RUNX2 silencing circuits also had lower 
mRNA levels of Acan, 19.4% and 33.2% respectively, at day 14 (Figure 4-5a). Despite the 
downregulated Acan gene expression, higher amounts of sGAG-rich matrix were accumulated at 
day 21 and day 28 in cultures of cells expressing 2cis-RUNX2 silencing compared to their 
corresponding scramble controls (Figure 4-6b). Although 3cis-shRunx2 cultures did not 
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accumulate higher levels of matrix compared to scramble controls at either time point, they are the 
only group that exhibited no trend of matrix loss from day 21 to day 28 (Figure 4-6c).  
 
Figure 4-5. Gene expression of early and late chondrogenic markers under the regulation of cis-shRunx2 gene 
circuits. Quantification of mRNA expression (relative to day 0 and the housekeeping genes Hprt and Ppia) of (a) 
Acan, (b) Col10a1), and (c) Mmp13 in monolayer ATDC5 cultures expressing cis-shRunx2 gene circuits or scramble 
vectors at day 14 and day 21. Data represented as mean ± s.e.m. Significant difference between groups at each time 
point (n=4 from two independent transduction experiments) is indicated by * P<0.05, ** P<0.01, ***P<0.001, 
****P<0.0001 by two-way ANOVA with Tukey’s multiple comparison method.  
85 
 
 
Figure 4-6. Effects of cis-shRunx2 gene circuits on matrix accumulation. Fold change (%, relative to day 21 
scramble controls) in sGAG accumulation by (a) 1cis-, (b) 2cis-, and (c) 3cis-RUNX2 silencing gene circuit at day 21 
and 28. Data represented as mean ± s.e.m. Significant difference between groups at each time point (n=6 from two 
independent transduction experiments) is indicated by * P<0.05, ** P<0.01, ***P<0.001, ****P<0.0001 by two-way 
ANOVA with Tukey’s multiple comparison method.  
4.3.4 Activity of RUNX2 Suppressing Gene Circuits in Response to Phosphate 
To examine the potential of cis-shRunx2 gene circuits to resist upregulation of 
hypertrophic markers in response to an exogenous cue, we supplemented the differentiation 
medium with 5mM βGP after ATDC5 cells expressing either 1cis- or 3cis- shRunx2 were 
chondrogenically induced for 7 days. In response to βGP, the activity of both the 1cis promoter 
and 1cis-shRunx2 gene circuit increased between day 9 and 20, with the maximum increases 
occurring around day 15 in both cultures (Figure 4-7a&b). However, the levels of stimulated 
activity by βGP differed between the 1cis-scramble and 1cis-shRunx2 cultures, and cells 
expressing 1cis-shRunx2 exhibited a lower percentage of increase compared to the scramble 
controls (24.1% vs. 31.1%, Figure 4-7c). Similarly, 3cis-shRunx2 cultures showed more 
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resistance to βGP-induced activity increase compared to 3cis-scramble controls (27.0% vs. 34.0%, 
Figure 4-7d-f).  
 
Figure 4-7. Activity of cis-shRunx2 gene circuits in response to phosphate. (a) Total luciferase activity of cultures 
expressing 1cis-Luc-shRunx2/scramble before and after βGP (5mM) treatment. (b) Relative activity increased (%, 
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normalized to non-treated cultures at each time point) in response to βGP after day 9. (c) Overall activity increase in 
1cis-Luc-shRunx2/scramble cultures between day 9 and 20. (d) Total luciferase activity of cultures expressing 3cis-
Luc-shRunx2/scramble before and after βGP (5mM) treatment. (e) Relative activity increased (%, normalized to non-
treated cultures at each time point) in response to βGP after day 9. (f) Overall activity increase in 3cis-Luc-
shRunx2/scramble cultures between day 9 and 20. Data represented as mean ± s.e.m. Significant difference in (c, n=3) 
and (f, n=3) is indicated by * P<0.05 by unpaired t-test. 
4.3.5 Effects of the 3cis-shRunx2 Gene Circuit on Chondrogenesis in Pellet Cultures 
To determine if the strongest RUNX2 silencing gene circuit enhances matrix accumulation 
by inhibiting the maturation-associated degradation, we monitored the progression of 
chondrogenesis in ATDC5 cell pellets expressing the 3cis-shRunx2 circuit (luciferase free) for five 
weeks. In the 3cis-scramble pellets, evident accumulation of sGAG-rich matrix was observed by 
day 14 in the form of nodules that were stained positive by Alcian blue dye (Figure 4-8a). Within 
these chondrogenic aggregates, little RUNX2 expression was detected by immunohistochemistry. 
By day 21, a further increase of matrix accumulation occurred, accompanied by the peak 
expression of RUNX2 (Figure 4-8b&c). Following this upregulation, loss of matrix started to 
become noticeable within certain regions of the chondrogenic aggregates by day 28. By the end of 
week 5, the majority of tissues formed by 3cis-scramble cells was stained negative by Alcian blue 
dye. In contrast to the elevated level of RUNX2 protein expression at day 21 in the 3cis-scramble 
pellets, the presence of RUNX2 was barely detectable in the 3cis-shRunx2 pellets (Figure 4-
9b&d). Despite such a difference, both groups of pellets showed similar morphologies of 
chondrocytes and levels of Alcian blue and type X collagen staining within their chondrogenic 
aggregates at this time point (Figure 4-9a-f). However, by day 35, a higher amount of matrix was 
retained in the 3cis-shRunx2 pellets compared to scramble controls (Figure 4-9g&h).  
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Figure 4-8. Chondrogenesis and maturation in ATDC5 pellets. Alcian blue staining of 3cis-scramble pellets at 
(a) 20× and (b) 40× magnification during five-week chondrogenic differentiation. (c) RUNX2 IHC staining of the 
chondrogenic regions within the pellets at each time point. Representative images from pellets of three independent 
transduction experiments. 
 
Figure 4-9. Effects of 3cis-shRunx2 on chondrogenic maturation in 3D ATDC5 model. Alcian blue staining of 
3cis-shRunx2 pellets and 3cis-scramble pellets at (a & b) day 21 and (g & h) day 35. (c & d) RUNX2 and (e & f) ColX 
IHC staining at day 21. Representative images from pellets of three independent transduction experiments were taken 
at 20× or 40×. 
4.3.6 Effects of RUNX2 Suppressing Gene Circuits on Matrix Accumulation in mMSC 
Pellets 
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To examine if the activity of RUNX2 silencing gene circuits also improves the 
accumulation of matrix by MdChs, we created polyclonal murine MSC cell populations that stably 
express cis-Luc-shRunx2 gene circuits and monitored the chondrogenesis of these cells in pellet 
cultures for eight weeks. In the 3cis-Luc-scramble pellets, accumulation of sGAG-rich matrix was 
observed by day 28 and further increased by day 42 (Figure 4-10a&b). Within the following two 
weeks, a small amount of matrix loss occurred together with the slight enlargement of cells within 
the chondrogenic regions (Figure 4-10c). Compared to their scramble controls, 3cis-Luc-shRunx2 
pellets deposited less matrix by day 28 but were able to accumulate more by day 42 (Figure 4-
10d&e). At the end of week 8, 3cis-Luc-shRunx2 pellets also retained a higher amount of matrix 
than the scramble controls (Figure 4-10f). Similarly, both 1cis- and 2cis-Luc-shRunx2 pellets 
enhanced matrix accumulation compared to their corresponding scramble controls by the end of 
culture; however, the difference between 1cis- gene circuit and its scramble control were less 
noticeable compared to their 2cis- and 3cis- counterparts (Figure 4-11).  
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Figure 4-10. Effects of 3cis-shRunx2 on chondrogenesis in murine MSC pellets. Alcian blue staining of 3cis-
shRunx2 pellets and 3cis-scramble pellets at (a & d) day 28, (b & e) day 42, and (c & f) day 56. Representative images 
from pellets of two independent transduction experiments were taken at 40×. 
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Figure 4-11. Effects of 1cis- and 2cis-shRunx2 on matrix accumulation during murine chondrogenesis. Alcian 
blue staining of (a & b) 1cis-shRunx2/scramble pellets and (c & d) 2cis- shRunx2/scramble pellets at day 28. 
Representative images from pellets of two independent transduction experiments were taken at 40×. 
4.4 Discussion & Conclusion 
MSCs have great proliferative and chondrogenic potential, making them promising candidates to 
replace articular chondrocytes for cell-based cartilage repair. Despite these advantages, the long-
term effectiveness of MSC-based cartilage regeneration is hampered by the preprogrammed 
differentiation to chondrocyte hypertrophy and maturation-associated matrix degradation. Here, 
we demonstrated that the synthetic Col10a1-like cis promoters can initiate RNAi of Runx2 in 
chondrocytes that are transitioning to the pre-hypertrophic phenotype in response to the increasing 
intracellular RUNX2 activity without interfering with early chondrogenesis of MSCs. The induced 
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loss of RUNX2 function in turn negatively regulates the activity of the cis-shRunx2 gene circuit, 
allowing MSC-derived chondrocytes to resist upregulation of RUNX2 during hypertrophy and 
maturation-associated matrix degradation. Our findings highlighted three key features of the cis-
shRunx2 gene circuit: 1) the phenotype-specific activation of RNAi, 2) the closed-loop 
intracellular negative-feedback regulation, and 3) the tunable steady-state level of RUNX2 
repression and dynamics.  
The cis-shRunx2 gene circuit relies on its Col10a1-like cis promoter to induce hypertrophy-
specific RUNX2 silencing. The specific expression of Col10a1 in pre-hypertrophic and 
hypertrophic chondrocytes requires the binding of RUNX2 in addition to the recruitment of the 
general transcription factors near the transcription start site47,51,52, which usually reside within the 
basal region of mammalian polymerase II promoters. The 330-bp Col10a1 basal promoter we 
incorporated contains a highly conserved sequence that precisely describes the transcription start 
site of Col10a1 across species47, providing the DNA template that supports the assembly of the 
RNA polymerase II transcription initiation complex. Meanwhile, the two putative tandem-repeat 
within the 150-bp cis-enhancer ensures direct binding of RUNX247,53. As a result of the 
cooperative actions of these two regulatory elements, all three versions of cis promoter are 
sufficient to direct hypertrophy-specific transcription resembling the endogenous Col10a1 
promoter in differentiating chondrocytes. We capitalized on the compact size and phenotype-
specificity of the cis promoter to target shRunx2 expression exclusively in maturing chondrocytes 
using a lentiviral vector. Therefore, the suppression of early chondrogenesis can be avoided as the 
loss of RUNX2 function does not occur until MSCs fully differentiate into chondrocytes and 
transition to pre-hypertrophy. In addition, this approach allows each cell within a heterogenous 
cell population to downregulate RUNX2 according to its individual maturation clock. 
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The cis-shRunx2 gene circuits also establish closed-loop intracellular negative-feedback 
regulation of RUNX2, allowing differentiating chondrocytes to resist maturation dynamically in 
response to exogenous cues. The negative feedback motif of cis-shRunx2 utilizes RUNX2 activity 
as the central signal. In chondrocytes that are transitioning to hypertrophy, the cis promoter (the 
regulator) initiates the production of shRunx2 (the repressor) that downregulates RUNX2 (the 
signal molecule), which in turn decreases the transcriptional activity of the cis promoter (Figure 
4-12). The negative feedback regulation of chondrocyte maturation also occurs naturally (e.g., 
PTHrP/IHH feedback loop )54. During fetal development, Indian hedgehog (IHH), synthesized by 
hypertrophic chondrocytes, stimulates maturation and for resting chondrocytes to secrete 
parathyroid hormone-related protein (PTHrP)54. PTHrP, in turn, suppresses IHH production and 
hypertrophy55,56. However, the anti-hypertrophy effect of PTHrP is limited by the range of 
paracrine signaling as only chondrocytes near the ends of long bones secrete this factor. As a result, 
chondrocytes residing in the deeper zones will undergo hypertrophy and further terminal 
differentiation57. Free from the dependence on paracrine signaling, cis-shRunx2 gene circuits allow 
chondrocytes to resist maturation based their internal tendency to undergo hypertrophy, measured 
by RUNX2 activity. As a gatekeeper, RUNX2 mediates the signaling of many molecular and 
biophysical cues to stimulate chondrocyte9,12,13. Therefore, by inputting the intracellular RUNX2 
activity as the signal for the negative-feedback regulation, cells expressing cis-shRunx2 can 
dynamically adjust the level of silencing required to maintain their steady states (levels of RUNX2 
suppression) without needing to address the specific pathways underlying hypertrophy stimuli. 
Such a feature is demonstrated by our observations of the cis-shRunx2 cultures treated with βGP.  
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Figure 4-12. cis-shRunx2 gene circuit provides negative feedback regulation of RUNX2. 
The design of the cis-shRunx2 gene circuit provides the negative-feedback regulation of 
RUNX2 with a tunable steady-state (the level of RUNX2 silencing) and dynamics (when to reach 
steady-state) under the control of cis-enhancers. Steady-states and dynamics are two of the most 
important characteristics of a negative feedback loop58. When this motif is used to regulate 
transcription, a stronger promoter not only allows the system to reach steady-state faster but 
changes the repression threshold59. In the cis-shRunx2 gene circuit, its steady-state describes the 
percentage of RUNX2 repression at equilibrium. We observed that increasing the number copies 
of cis-enhancer in the gene circuit progressively enhanced RUNX2 silencing from 18% to nearly 
80%. Increasing the number of cis-enhancers also led to faster equilibrium of the activity of the 
gene circuits. Such behaviors likely resulted from the increased responsiveness to RUNX2 as 
additional binding sites were introduced by extra copies of cis-enhancers47,53. More importantly, 
the tunability of the cis-shRunx2 gene circuit potentially allows us to optimize the matrix 
accumulation by controlling the dynamics and the level of RUNX2 repression during 
chondrogenic differentiation. In this study, while 3cis-shRunx2 exhibited the strongest ability to 
silence RUNX2, its rapid progression to steady-state also caused silencing in undifferentiated 
ATDC5 cells and mMSCs. Although the actual level of RUNX2 repression was insufficient to 
inhibit chondrogenesis, it downregulated the gene expression of Acan during the early stages of 
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chondrogenesis. This likely explains why the increase of matrix accumulation did not occur in 
ATDC5 3cis-shRunx2 cultures until after day 21. In contrast, the activity of 2cis-shRunx2 reached 
steady-state after chondrocytes were fully differentiated. While this gene circuit caused little 
interference with the expression of Acan during the early phases of chondrocyte development, it 
only induced 30.4% of RUNX2 repression, potentially limiting its long-term effectiveness in 
inhibiting matrix degradation. Therefore, future studies that focus on how different cis-shRunx2 
gene circuits affect the matrix turnover and modification are critical to identifying the optimal 
design for cartilage regeneration. 
 It is also worth noting that the luciferase reporter played an indispensable role in revealing 
the three key features of the cis-shRunx2 gene circuits. Because their phenotype specificity limits 
the activity of these gene circuits to a small subpopulation of cells among the entire culture, the 
loss of RUNX2 is difficult to measure using techniques like western blotting. Thanks to the high 
sensitivity of the luciferase assay, subtle differences among the activity of the gene circuits can be 
amplified and monitored in real-time. Such an advantage allows us to accurately estimate the level 
of RUNX2 repression without needing to directly measure the protein expression of RUNX2. 
Finally, despite its evident enhancing effect on matrix accumulation, the cis-shRunx2 gene circuit 
did not completely block the maturation of chondrocyte in either ATDC5 or mMSC cultures. 
While the incomplete silencing of RUNX2 might have contributed to such observations, it might 
also suggest that the inhibition of transcription factors besides Runx2 is needed for chondrocytes 
to fully resist maturation. Using the cis-RNAi system developed in this study, future studies can 
conveniently target single or multiple pro-hypertrophic factors to further improve the matrix 
accumulation.  
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Chapter 5 Conclusion and Future Directions 
Regenerating articular cartilage from mesenchymal stem cells (MSCs) requires them to 
adopt and then maintain the stable phenotype of articular chondrocytes. Cartilage differentiation 
entails a series of well-coordinated signaling stimulation while cartilage homeostasis relies on the 
balanced anabolic and catabolic activity of chondrocytes which are subject to the actions of 
numerous biochemical and mechanical cues1,2. Conventional approaches based on growth factors 
and transgene overexpression have showed success in stimulating initial chondrogenesis. However, 
these methods are less effective in maintaining stable chondrocyte phenotype as fixed growth 
factor cocktails or forced overexpression of one/two genes cannot provide the versatile responses 
needed to cope with the constantly changing intracellular and environmental signals. 
The concept of the self-regulatory gene circuit proposed in this thesis highlighted the 
feasibility of introducing an artificial, negative-feedback regulatory pathway into the mammalian 
cells to target a specific signaling molecule – RUNX2. Therefore, modulated chondrocytes can 
dynamically counteract various external biochemical or biophysical cues that stimulate RUNX2 
activity. Additionally, our design here utilizes synthetic nucleotide elements that resemble the 
naturally occurring genetic modalities. For example, the cis promoters imitate the endogenous 
Col10a1 promoter; RNAi of Runx2 via miRNA-based shRNA also mimics the natural microRNA 
pathways. The similarity between this synthetic signaling cascade and endogenous regulatory 
machinery not only enhances the compatibility and efficacy of gene circuits but also minimizes 
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the stress on host cells. Meanwhile, the encouraging results demonstrated in this dissertation have 
also inspired much future work that could focuses on 1) helping us better understand the existing 
cis-shRunx2 gene circuit, 2) designing new gene circuits that employ novel tissue-specific 
promoters or target other regulatory pathways.  
5.1 Understand and Improve cis-shRunx2 Gene Circuit 
5.1.1 Improve Tunability  
In chapter 4, we have discussed the three main features of cis-shRunx2: 1) the phenotype-
specific activation of RNAi, 2) the closed-loop intracellular negative-feedback regulation, and 3) 
the tunable steady-state level of RUNX2 repression and dynamics. Among these, the ability to 
achieve tunable level of RUNX2 suppression is particularly appealing to us as we could potentially 
use it to fine-tune the behavior of target cells. However, as we increase the number of cis enhancers 
to increase RUNX2 silencing, loss of RUNX2 function started to occur earlier as well, which could 
potentially interfere with synthesis of aggrecan and type II collagen. Therefore, one of the next 
engineering milestones would be to decouple the dynamics and steady-states of the cis-
shRunx2 gene circuits. Specifically, if the levels of RUNX2 suppression could be adjusted 
without changing when the silencing activity reaches that steady state or vice versa, we could 
further optimize timing and dosing of RUNX2 silencing to maximize the matrix accumulation. To 
achieve this goal, tunability can be explored at two different levels of the intergradation of the gene 
circuit. Obviously, within a single cis-shRunx2 unit, different shRNA sequences could be 
examined to understand their contribution to both steady-state level of RUNX2 repression and 
silencing dynamics. However, we speculate the range of tunability provided by adjustment at this 
level is limited as current cis-shRunx2 gene circuits already employ one of the most potential 
siRNA sites on the mRNA of Runx23. Meanwhile, if the current cis-shRunx2 expression cassette 
is treated as a basic unit (one cis promoter plus one shRunx2), we could potentially introduce 
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multiple copies of the same unit or different ones (via a single vector, Figure 5-1) to achieve 
desired RUNX2 expression profile. To preliminarily test this hypothesis, we have transduced 
ATDC5 cells with the same 1cis-shRunx2 virus twice and examined if there is any change of 
activity in the culture. We observed an increased level of RUNX2 suppression with little change 
of dynamics (Figure 5-2). This observation suggests that this approach of tuning circuit activity is 
effective and can decouple the level of RUNX2 repression and when to reach steady-states. 
 
Figure 5-1. Diagram of gene circuits with multiple shRunx2 units. 
 
Figure 5-2. Activity between single and double 1cis-shRunx2 gene circuits. Total luciferase activity of ATDC5 
cultures that are transduced with 1cis-Luc-shRunx2 (a) once and (b) twice.  
5.1.2 Investigate Matrix Turnover  
In chapters 2 and 4, we independently observed improved matrix accumulation (sGAG) 
due to RUNX2 silencing. However, a healthy cartilage tissue relies on the balanced anabolic and 
catabolic activity from the resident chondrocytes. Therefore, understanding the effect of circuit 
activity on the matrix turnover would provide critical insights for us to choose among the different 
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versions of cis-shRunx2. Specifically, in the future long-term in vitro studies, both the retained 
matrix and degradation fragments of aggrecan and type II collagen should be measured, especially 
under the simulated inflammatory environments. These results could help us evaluate effects of 
cis-shRunx2 gene circuits at different stages of chondrogenic differentiation and use these data to 
design or fine-tune new gene circuits. In addition, mechanical properties of the final cartilage tissue 
constructs (gene circuits-modified MSCs encapsulated in scaffolds) developed under the control 
of different cis-shRunx2 gene circuits should be measured to examine if the improved phenotype 
contributes to a superior mechanical strength.  
5.2 Design New Gene Circuits 
This dissertation also showcased an iterative design process that includes establishment 
test system, independent validation of vector components, and verification of integrated gene 
circuits. Taking advantage of this established workflow, we could conveniently explore other 
target pathways that could be exploited to improve cartilage regeneration. Thanks to the similarity 
between miRNA-based shRNA and natural microRNA pathways, our gene circuit can be easily 
converted to induce expression of 1) microRNAs that promote chondrogenesis (e.g., mir4104), 2) 
shRNAs that inhibits other hypertrophy stimulators (e.g., MEF2C5), or 3) shRNAs that target 
matrix-degrading enzymes (e.g., ADAMTS4&56). The list of potential targets has been increasing 
at rapid pace fueled by our growing knowledge of cartilage development, the invention of genetic 
tools (e.g., high-throughput sequencing), and computation models. These advances have also 
promoted our understanding of mammalian tissue-specific promoters and their cis regulatory 
elements. Therefore, we have the potential of designing novel synthetic promoters which not only 
recapitulate the existing tissue-specificity but also hybrid features that are derived from multiple 
endogenous promoters. For our application, synthetic murine and human promoters that target 
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different stages of chondrocyte maturation would be next logical step to expand our library of gene 
circuits. For example, synthetic promoters that resembling endogenous promoters of Acan and 
Col2a1 can be used to provide expression of pro-chondrogenic microRNAs prior to the onset of 
hypertrophy to complement the function of cis-shRunx2. 
5.3 Challenges Associated with the Clinical Application of Gene Circuit  
Despite the promising potentials of gene circuit technology in tissue engineering 
applications, major hurdles for gene-enhanced cell therapy of cartilage repair include eliminating 
the risk of oncogene activation, maintaining long-term silencing efficacy, and demonstrating 
robust clinical superiority and cost-effective against current treatment strategies. Safety concerns 
associated with the possible activation of oncogene due to the integration of gene vector, especially 
lentiviral vectors, has been one of the major challenges that hinder the wider application of this 
type of gene therapy. However, recent advances and positive clinical results in hematopoietic stem 
cell- and T-cell based gene therapies have been improving the public acceptance as well as attitude 
from regulatory agencies. More importantly, this attitude shift has also motivated more effort to 
improve the vector design and reduce insertional mutagenesis from both academic research 
laboratories and industrial organizations. Specifically, for cartilage tissue engineering, the gene 
therapy-based repair strategy is faced with a high level of competition from alternative treatments. 
Since posttraumatic osteoarthritis is not life-threatening, conservative treatments might be 
preferred until the gene circuit-based cartilage repair methods exhibit significantly superior long-
term outcomes, such as restoration of mechanical functions and delayed onset of osteoarthritis. 
Also, the current pricing of gene therapy treatments is expected to be significantly higher than 
standard procedures due to the individualized manufacture requirements. Therefore, both 
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irrefutable evidence of outcome improvements and significant reduction of manufacture cost are 
also prerequisites for the clinical adoption of gene circuit-based cartilage repair. 
5.4 Tissue Engineering Application of Phosphate 
In Chapter 3, we also demonstrated the biphasic effect of phosphate on early 
chondrogenesis. Specifically, moderate Pi abundance enhanced production of aggrecan and type 
II collagen whereas high Pi abundance inhibited chondrogenic differentiation. For cartilage tissue 
engineering, the anabolic effect of Pi on matrix synthesis could propose a cost-effective method to 
improve MSC-based cartilage regeneration. However, application of Pi during chondrogenesis of 
progenitor cells requires careful calibration as it can easily induce mineralization when 
supplemented at the wrong concentration. To further investigate the feasibility of using Pi to 
improve production of aggrecan and type II collagen, we will need to confirm the anabolic effect 
of Pi in human MSCs. Since the effect of Pi also depends on the maturation state of 
chondrocytes/MSCs, a systematic characterization of cellular response at various stages of 
chondrogenesis would be necessary to identify the window of opportunity for Pi-induced matrix 
production. 
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